Citation: Kringel, D.; Malkusch, S.; Kalso, E.; Lötsch, J. Computational Functional Genomics-Based AmpliSeq™ Panel for Next-Generation Sequencing of Key Genes of Pain. Int. J. Mol. Sci. 2021, 22, 878. https://doi.org/10.3390/ijms22020878

Received: 24 November 2020  
Accepted: 12 January 2021  
Published: 16 January 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Abstract: The genetic background of pain is becoming increasingly well understood, which opens up possibilities for predicting the individual risk of persistent pain and the use of tailored therapies adapted to the variant pattern of the patient’s pain-relevant genes. The individual variant pattern of pain-relevant genes is accessible via next-generation sequencing, although the analysis of all “pain genes” would be expensive. Here, we report on the development of a cost-effective next generation sequencing-based pain-genotyping assay comprising the development of a customized AmpliSeq™ panel and bioinformatics approaches that condensate the genetic information of pain by identifying the most representative genes. The panel includes 29 key genes that have been shown to cover 70% of the biological functions exerted by a list of 540 so-called “pain genes” derived from transgenic mice experiments. These were supplemented by 43 additional genes that had been independently proposed as relevant for persistent pain. The functional genomics covered by the resulting 72 genes is particularly represented by mitogen-activated protein kinase of extracellular signal-regulated kinase and cytokine production and secretion. The present genotyping assay was established in 61 subjects of Caucasian ethnicity and investigates the functional role of the selected genes in the context of the known genetic architecture of pain without seeking functional associations for pain. The assay identified a total of 691 genetic variants, of which many have reports for a clinical relevance for pain or in another context. The assay is applicable for small to large-scale experimental setups at contemporary genotyping costs.

Keywords: next generation sequencing; human genomics; pain genetics; pharmacogenomics; computational functional genomics; data science; knowledge discovery

1. Introduction

A genetic background of pain plays a role in rare hereditary extreme phenotypes that cause either pain insensitivity [1] or paroxysmal pain disorders [2], in the perception of acute pain [3], in the risk of pain persistence after a triggering event [4], or in the response to pharmacological [5] or non-pharmacological [6] pain treatments. The involvement of 540 “pain genes” in pain is supported by robust evidence [7,8], and further suggestions have been communicated [9,10]. With predominantly small effects exerted by common genetic variants [11], a breakthrough in the genetic profiling of individual risks, as occasionally expected [12], has not yet really been achieved [13]. Instead, this seems to be linked to a complex pattern of functional genetic variants [14], which is being discovered in an evolutionary rather than revolutionary way, which is supported by technical advances over the last decade [15] that allow to establish genotype versus phenotype associations for thousands of genetic variants in a still manageable small number of patients [14,16].
As a basis for the association of human genotypes with pain and the risk for its persistence, we propose a set of 29 genes as key players among the currently known pain-relevant genes [17]. Specifically, the functional genomics-based architecture of pain has been presented as a polyhierarchy of biological processes [8] based on the organization of the Gene Ontology knowledge base that captures the current knowledge about the biological roles of all genes and their respective products [18,19]. With the 29 genes, a respective representation created with 540 pain-relevant genes could be reconstructed by 70%, based on a bioinformatics analysis of the Gene Ontology knowledge base [17].

The present report describes the development of a genotyping assay for these 29 genes, with extension by further genes based on proposed importance for persistent pain to take full advantage of the technical specifications of the AmpliSeq\textsuperscript{TM} gene sequencing library technique (Figure 1), resulting in a set of $d = 72$ genes (Table 1) continuing the research path of functional genomics of pain that has been pursued in previous reports [7,9,10,20]. Here, (i) the assembly of the present set of genes is reported along with (ii) a computational analysis of its functional genomics and (iii) its establishment in a subset of samples from a cohort of patients undergoing breast cancer surgery [21], together with (iv) an evidence-based analysis of known functional implications of the variants identified in these samples, although without aiming for a functional association in the present cohort.

Table 1. Overview of the $n = 72$ genes contained in the proposed NGS panel. Subset 1 includes $d = 29$ genes identified using a computational functional genomics-based approach in which the gene sets are reduced to the most relevant items based on the importance of the gene within the polyhierarchy of biological processes characterizing the disease [17]. Subset 2 resulted from the intersection of two proposed sets of human genes involved in modulating the risk or clinical course of persistent pain “Mogil” [9], and “Zorina-Lichtenwalter”.

| Gene Symbol | NCBI | Gene Description | Reference |
|-------------|------|------------------|-----------|
| ADRA2A      | 150  | Adrenoceptor alpha 2A | [22]      |
| ADRB2 *     | 154  | Adrenoceptor beta 2 | [23]      |
| AGER        | 177  | Advanced glycosylation end-product specific receptor | [24] |
| APOE *      | 348  | Apolipoprotein E | [25]      |
| CCL21       | 6366 | C-C motif chemokine ligand 21 | [26] |
| CCL5        | 6352 | C-C motif chemokine ligand 5 | [27] |
| CCR2        | 729230 | C-C motif chemokine receptor 2 | [28] |
| CCR7        | 1236 | C-C motif chemokine receptor 7 | [29] |
| CD4         | 920  | CD4 molecule | [30]      |
| CD40        | 958  | CD40 molecule | [31]      |
| CD74        | 972  | CD74 molecule | [32]      |
| CHRNA7      | 1139 | Cholinergic receptor nicotinic alpha 7 subunit | [33] |
| DRD1        | 1812 | Dopamine receptor D1 | [34] |
| DRD2 *      | 1813 | Dopamine receptor D2 | [34] |
| EDN1        | 1906 | Endothelin 1 | [35]      |
| F2R         | 2149 | Coagulation Factor II thrombin receptor | [36] |
| F2RL1       | 2150 | F2R like trypsin Receptor 1 | [36] |
| IFNG        | 3458 | Interferon gamma | [37] |
| IL1B *      | 3553 | Interleukin 1 beta | [38] |
| IL6         | 3569 | Interleukin 6 | [39]      |
| LYN         | 4067 | LYN proto-oncogene, Src family tyrosine kinase | [40] |
| MAPK1       | 5594 | Mitogen-activated protein kinase 1 | [41] |
| OPRM1 *     | 4988 | Opioid receptor mu 1 | [42] |
| P2RX7 *     | 5027 | Purinergic receptor P2X 7 | [43] |
| PRKCA       | 5578 | Protein kinase C alpha | [44] |
| PRKCD       | 5580 | Protein kinase C delta | [45] |
| TLR4        | 7099 | Toll-like receptor 4 | [46] |
| TLR9        | 54106 | Toll-like receptor 9 | [47] |
| TNF *       | 7124 | Tumor necrosis factor | [48] |
Table 1. Cont.

| Gene Symbol | NCBI | Gene Description | Reference |
|-------------|------|------------------|-----------|
| **Subset #2** | | | |
| ACAN | 176 | Aggrecan | [49] |
| ACE | 1636 | Angiotensin I converting enzyme | [50] |
| ADRA1D | 146 | Adrenoceptor alpha 1D | [51] |
| ADRA2C | 152 | Adrenoceptor alpha 2C | [52] |
| ADB2 | 154 | Adrenoceptor beta 2 | [53] |
| APOE | 348 | Apolipoprotein E | [25] |
| AR | 367 | Androgen receptor | [54] |
| CALCA | 796 | Calcitonin related polypeptide alpha | [55] |
| CASP9 | 842 | Caspase 9 | [56] |
| CFTR | 1080 | CF transmembrane conductance regulator | [57] |
| CRHBP | 1393 | Corticotropin releasing hormone binding protein | [58] |
| COMT | 1312 | Catechol-O-methyltransferase | [59] |
| DRD2 * | 1813 | Dopamine receptor D2 | [34] |
| DRD4 | 1815 | Dopamine receptor D4 | [60] |
| ESR1 | 2099 | Estrogen receptor 1 | [61] |
| GCH1 | 1312 | Catechol-O-methyltransferase | [59] |
| GDF5 | 8200 | Growth differentiation factor 5 | [63] |
| GSTM1 | 2944 | Glutathione S-transferase mu 1 | [64] |
| HLA-DRB1 | 3123 | Major histocompatibility complex, class II, DR beta 1 | [65] |
| HTR2A | 3356 | 5-hydroxytryptamine receptor 2A | [66] |
| IL1A | 3552 | Interleukin 1 alpha | [67] |
| IL10 | 3586 | Interleukin 10 | [68] |
| IL1B * | 3553 | Interleukin 1 beta | [38] |
| IL1RN | 3557 | Interleukin 1 receptor antagonist | [69] |
| KCNS1 | 3787 | Potassium voltage-gated channel modifier subfamily S member 1 | [71] |
| MAOA | 4128 | Monoamine oxidase A | [72] |
| M2R | 4158 | Melanocortin 2 receptor | [73] |
| MTHFD1 | 4522 | Methylenetetrahydrofolate dehydrogenase, cyclohydrolase and formyltetrahydrofolate synthetase 1 | [74] |
| MTR | 4552 | 5-methyltetrahydrofolate-homocysteine methyltransferase reductase | [75] |
| NFkBIA | 4792 | NFkB inhibitor alpha | [76] |
| NR3C1 | 2908 | Nuclear receptor subfamily 3 group C member 1 | [77] |
| OPRM1 * | 4988 | Opioid receptor mu 1 | [42] |
| P2RX7 * | 5027 | Purinergic receptor P2X 7 | [43] |
| PGR | 5241 | Progesterone receptor | [78] |
| POMC | 5443 | Proopiomelanocortin | [79] |
| PRSS1 | 5644 | Serine protease 1 | [80] |
| PTGS2 | 5743 | Prostaglandin-endoperoxide synthase 2 | [81] |
| SCN9A | 6335 | Sodium voltage-gated channel alpha subunit 9 | [82] |
| SERPINA6 | 866 | Serpin family A member 6 | [83] |
| SHMT1 | 6470 | Serine hydroxy methyltransferase 1 | [84] |
| SMAD3 | 4088 | SMAD family member 3 | [85] |
| SOD2 | 6648 | Superoxide dismutase 2 | [86] |
| SPINK1 | 6690 | Serine peptidase inhibitor, Kazal type 1 | [57] |
| STAT6 | 6778 | Signal transducer and activator of transcription 6 | [87] |
| TGFBI | 7140 | Transforming growth factor beta 1 | [88] |
| TNF * | 7124 | Tumor necrosis factor | [48] |
| TRPA1 | 8989 | Transient receptor potential cation channel subfamily A member 1 | [89] |
| TRPM8 | 79054 | Transient receptor potential cation channel subfamily M member 8 | [89] |
| TRPV1 | 7442 | Transient receptor potential cation channel subfamily V member 1 | [89] |

*: Gene occurs in both subsets.
Assembly of the pain-relevant gene set forming the proposed NGS panel from various sources of evidence. The Venn diagram [90] visualizes the overlaps between the 29 key genes in the functional genomic representation of pain (“Lippmann” [17]) (subset 1 of the present NGS panel) and the two independent alternative proposals (“Mogil” [9] and “Zorina-Lichtenwalter” [10]) included as subset 2. The colors of the areas correspond to the colors of the adjacent names of the respective gene set. In addition, a set of \( d = 540 \) genes is indicated which have been empirically identified as relevant to pain and are either listed in the PainGenes database (http://www.jbldesign.com/jmogil/enter.html [7]) or were recognized as causing human hereditary diseases associated with extreme pain phenotypes, regulated in chronic pain in at least three studies including human association studies, or being targets of novel analgesics [91]. In addition, a further set of genes is included that belong to an NGS panel in an earlier approach to human genes relevant for the persistence of pain (“Kringel 1” [20]) The black dashed line surrounds the genes of the present NGS panel. The figure has been created using the R software package (version 4.0.2 for Linux; http://CRAN.R-project.org/ [92]) and the library “venn” (https://cran.r-project.org/package=venn [93]).

2. Results
2.1. Participants and Descriptive Data

The NGS assay of the proposed set of 72 human genes relevant for persistent pain, was established in 61 genomic DNA samples available from a cohort of patients after breast cancer surgery [94] and including 55 subjects without pain and six patients with persistent pain, which corresponded to the ratio of persistent pain versus no pain in the entire cohort in order to resemble a random sample of subjects in terms of pain as much as possible.
2.2. Main Results

As applied previously [95], only exons including 25 bases of padding around all targeted coding regions for which the realized read-depths for each nucleotide was higher than 20 were contemplated as successfully analyzed. With this acceptance criterion, the whole or almost whole coverage of the relevant sequences was obtained. The NGS sequencing process of the whole patient cohort required seven separate runs, each with samples of \( n = 9 \) or \( n = 10 \) patients. Coverage statistics were analogous between all runs and matched the scope of accepted quality levels [20,21,94]. A median of \( 4.55 \times 10^6 \) reads per run was produced. The mean depth was close to 200 reads, the mean read length of called bases resulted in 215 bases and average chip loading was 67% (Figure 2). To establish a sequencing output with a high density of ISPs on a sequencing chip, the chip loading value should exceed 60% (Life Technologies, Carlsbad, CA, USA). The generated results of all NGS runs matched with the results obtained with Sanger sequencing of random samples, meaning the accordance of nucleotide sequences between next generation sequencing and Sanger sequencing was 100% in all validated samples.

Following elimination of nucleotides agreeing with the standard human genome sequence GRCh37 g1k (dated February 2009), the result of the NGS consisted of a vector of nucleotide information about the \( d = 69 \) genes for each individual DNA sample. This vector had a length equaling the set union of the number of chromosomal positions in which a non-reference nucleotide had been found in any probe of the actual cohort. Specifically, a total of 691 genetic variants were found, of which 161 were exonic, 22 intergenic, 255 intronic,
and 215 variants were located in the 3′-UTR and 38 variants in the 5′-UTR (Figure 3). Three genes (IFNG, GSTM1, and CXCL8) were not represented in the final set of genetic variants. Panel design and assay quality parameters were re-examined with positive results. The read gene length provided an explanation for the absence of variants (Figure 3). That is, the three genes were among the shortest genes in the available panels. In fact, the number of variants detected was significantly correlated with the total number of nucleotides read (total number of variants: robust correlation coefficient: 0.612, \( p = 1.116 \times 10^{-8} \), exonic variants only: robust correlation coefficient: 0.398, \( p = 0.00054 \)). The number of nucleotides read per gene also matched well with the gene length queried from the database “org.Hs.eg.db” (robust correlation coefficient: 0.8633, \( p < 2.22 \times 10^{-16} \).

2.3. Other Analyses

The d = 29 genes have been shown to cover 70% of the DAG emerging from 540 pain genes, i.e., can be regarded to represent pain completely to this extent [17]. However, as the present panel had been filled with further genes, the present analyses aimed to functionally characterize the set of d = 72 genes. This was approached by computational querying of the knowledge about the function of human genes recorded in the knowledge base of gene ontology (GO). Over-representation analysis (ORA) identified 70 GO terms as significantly associated with the set of 72 genes, more often than randomly expected, at the selected \( p \)-value threshold of 5 \( \times 10^{-15} \) with correction for multiple tests according to Bonferroni. Computed ABC analysis of the remarkableness of the GO terms qualifying as headlines to describe significant branches of the obtained polyhierarchy categorized d = 14 terms into ABC set “A” indicating the most important items (Figure 4). Further reduction of the number of GO terms by subsumption of adjacent branches of the polyhierarchy to the next suitable unifying term upwards the hierarchy led to six functional areas covered by the 72 genes.
Figure 4. Computational functional genomics perspective on the biological processes in which the genes analyzed with the proposed NGS panel are involved. The figure displays the results of an overrepresentation analysis (ORA; \( p \)-value threshold, \( t_p = 5 \times 10^{-15} \) and Bonferroni \( \alpha \) correction) of the 72 genes included in the present NGS panel (Table 1). (A) Bar plot of the gene relevance in the functional genomics representation of the present gene set. As a basis for the selection of the most relevant terms to describe the directed acyclic graph (DAG [97]) representing the polyhierarchical structure of the Gene Ontology database, i.e., the terms that can serve as headlines for each branch of the DAG, the remarkableness measure was previously introduced [98]. The bar plot shows the relevance of GO terms in decreasing order of the remarkableness measure. The blue bars indicate the most relevant terms selected by an item categorization technique, implemented as a computed ABC analysis [99]. (B) The ABC plot (blue line) shows the cumulative distribution function of the remarkableness measure with the limits between sets A, B and C indicate as red lines. The results show that 14 GO terms belonged to ABC set “A” and were therefore considered as most relevant to the DAG. (C) Top-down representation of the annotations (GO terms) representing a systems biology perspective of the biological processes modulated by the set of 72 genes included in the present NGS panel. Each ellipse represents a GO term. The graphical representation follows the standard of the GO knowledge base, where GO terms are related to each other by “is-a”, “part-of”, “has-a” and “regulates” relationships forming a branching polyhierarchy organized in a directed acyclic graph (DAG [97]). The color coding is as follows: No color: GO terms that are important for the DAG’s structure but do not have a significant \( p \)-value in Fisher’s exact tests. Red: Significantly overrepresented nodes. Green: Terms at the end (detail) of a branch of the DAG. In addition, the node’s text will be colored in blue to indicate that this node is a detail. Yellow: Significant nodes with highest remarkableness in each path from a detail to the root, i.e., the so-called “headlines”. The margins indicate over by its red color. Violet: Functional areas, i.e., terms selected to describe the parts below them in the DAG most concisely. The figure has been created using the R software package (version 4.0.2 for Linux; http://CRAN.R-project.org/ [92]) and the R libraries “ABCanalysis” (http://cran.r-project.org/package=ABCanalysis [99]), “ggplot2” (https://cran.r-project.org/package=ggplot2 [96]) and “dbtORA” (https://github.com/IME-TMP-FFM/dbtORA [100]).
These areas included: (i) the “regulation of localization” (GO:0032879), which mainly concerned the regulation of protein secretion (GO:0050708); (ii) “response to a stimulus” (GO:0050896) (Figure 5), especially to a chemical stimulus (GO: 0042221) and converged to “cytokine-mediated signaling” (GO:0019221) and the MAPK cascade (GO:0043410); (iii) the “metabolic process” (GO:0008152), which also converged to the MAPK cascade, the ERK1 and ERK2 cascade (GO: 007031), and the protein kinases (GO:0045860); (iv) the “multicellular organism process” (GO:0032501), which mainly involves cytokine production (GO:0001819), (v) “signaling” (GO:0023052), which in turn converges to the MAPK cascade, and (vi) finally, the non-specific “regulation of biological quality” (GO:0065008), which is considered to be relevant in the maintenance of homeostasis. Taken together, the set of \( n = 72 \) genes was functionally mainly involved in the mitogen-activated protein kinase of extracellular signal-regulated kinase, which, in interaction with cytokine production and secretion, indicated the control of immune and inflammatory processes in pain.

**Figure 5.** Detail of the directed acyclic graph (DAG [97]) shown in Figure 4, displaying the polyhierarchical structure of the Gene Ontology database (“point of view”) below the GO term “response to stimulus” (GO:0050896). This was one of the major biological processes identified by a functional genomics analysis aiming at characteristics of pain and defined as “Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus. The process begins with detection of the stimulus and ends with a change in state or activity or the cell or organism” [19]. The color coding is as follows: No color: GO terms that are important for the DAG’s structure but do not have a significant \( p \)-value in Fisher’s exact tests. Red: Significantly overrepresented nodes. Green: Terms at the end (detail) of a branch of the DAG. In addition, the node’s text will be colored in blue to indicate that this node is a detail. Yellow: Significant nodes with highest remarkableness in each path from a detail to the root, i.e., the so-called “headlines”. The margins indicate over by its red color. Violet: Functional areas, i.e., terms selected to describe the parts below them in the DAG most concisely. The figure has been created using the R software package (version 4.0.2 for Linux; http://CRAN.R-project.org/ [92]) and the library “dbtORA” (https://github.com/IME-TMP-FFM/dbtORA [100]).

3. Discussion

The primary subset of the present panel of pain-relevant genes represents key genes of pain that had emerged in a computational functional genomics-based analysis that considered the position of biological processes in which these genes were involved in the polyhierarchical presentation of pain [17]. In a previous analysis of the functional genomics of pain [8], the biological functions characterizing pain had been identified to comprise 12 different components. Specifically, main functional areas were “behavior”, “response to wounding” and “response to organic substance”, which are sub-terms of the GO term “response to stimulus”. In addition, ion homeostasis and transport, the synaptic transmission of nociceptive input and intracellular signal transduction including the
G-protein coupled receptor-signaling pathway as well as anatomical structure development and regulation of (multicellular) system processes completed the full functional picture of pain. In a later analysis [17], the present subset 1 of \( n = 29 \) best-scoring genes was found to identify the GO terms forming the complete polyhierarchy with precision and recall of more than 70%. Thus, the present subset 1 includes genes which best reflect the functional biology of pain. For comparison, when using a random sample of \( n = 29 \) genes from the 540 pain-relevant genes, the average recall of the GO terms of the pain-DAG was only 1.77% [17]. The relevance for pain in general was also supported by the observation that for the currently 29 genes a significantly higher hit rate of drug targets was achieved than for a random sample of 29 genes among the 540 pain genes [17]. Hence, several lines of evidence provide support that subset 1 can be considered as a pain-relevant selection of genes.

It was technically possible to add more genes without increasing the analytical cost, and this option was chosen by adding subset 2, which uses previous and independent efforts to select pain-relevant genes [9,10]. This shifted the functional genomics of pain covered by the recent NGS Panel, resulting in the need for a new analysis, which led to an emphasis on immune and inflammatory processes in the functional genomics of pain covered by the current NGS panel, particularly represented by the mitogen-activated protein kinase of extracellular signal-regulated kinase and cytokine production and secretion.

Thus, the present panel provides a key set of pain genes that has been derived from a computer-aided functional genomics analysis [17] of 540 genes of the PainGenes database [7]. Although this covers 70% of the biological processes in which the 540 genes are involved, it is not an exhaustive set of genes of interest for pain. The genes in the PainGenes database were included based on studies in transgenic mice, with the condition that at least one statistically significant difference was reported between the mutated mice and their concurrently tested wild-type controls. However, alternative approaches, including by the authors of the PainGenes database [9], used different criteria, such as reported associations with clinical pain, resulting in additional gene sets that were suggested to be pain relevant. A selection of these genes was included as subset 2 in the present panel, and in addition, additional genes from these proposals were included in an earlier, similarly designed NGS panel [20,95,101]. For example, the \textit{COMT} genes were added, which were extensively studied in connection with pain modulation [102], but were not included in the important subset 1 of the present panel, but were members of subset 2.

3.1. Discussion of Main Results
3.1.1. Technical Considerations

Since 2008, when sequencing switched from Sanger-based to NGS technologies, the cost per raw megabase has been significantly below the expectations predicted by the reciprocal of Moore’s law, where the latter is an empirical observation from computer hardware engineering and describes technological developments that are widely regarded as successful (for data, see https://www.genome.gov/about-genomics/fact-sheets/DNA-Sequencing-Costs-Data). The panel presented here, fits well into the current costs. Our sequencing project with the Ion Torrent\textsuperscript{TM} platform using the personal genome machine with 318\textsuperscript{TM} chips cost approx. € 630 per sequencing run while the cost per raw megabase of the 72 genes in 56 DNA samples required approximately € 0.20 per Mb. While the sequencing cost per run for the Torrent\textsuperscript{TM} and Ilumina MiSeq are comparable, the investment costs for the MiSeq sequencer are higher, but this machine has a higher throughput, which reflects in a slightly reduced sequencing cost per megabase [103].

3.1.2. Functional Involvement of Genes in Biological Processes

The selection of genes relied on empirical evidence of their involvement in pain. For subset #1 (\( d = 29 \)). This had been shown for all of the genes in the original paper [17]. This subset includes \( d = 29 \) genes identified using a computational functional genomics-based approach in which the gene sets are reduced to the most relevant items based on
the importance of the gene within the polyhierarchy of biological processes characterizing pain. Subset #2 resulted from two proposed sets of human genes involved in modulating the risk or clinical course of persistent pain “Mogil” [9] and “Zorina-Lichtenwalter” [10]. The chosen set of genes for subset ‘2 includes the intersection from both alternative proposals aiming at similar phenotypes. However, when analyzing these alternatives for mutual agreement, an overlap of \( n = 50 \) could be observed. Combining all proposals into a large panel was not an option due to the technical limitations of the IonTorrent™ restricting the panel size to 500 kb (pipeline version 5.6.2, Carlsbad, CA, USA).

Both subsets comprised genes associated with the mesolimbic dopaminergic system, i.e., \( \text{DRD1, DRD2, DRD3, DRD4} \) which code for dopamine receptors which play an important role in pain modulation, suggesting that dopamine can modulate pain signals by acting at both presynaptic and postsynaptic targets [104]. Further genes were involved in cytokine production (\( \text{CCL21, CCL5, CCR2, CCR7} \)) and there is significant evidence showing that certain cytokines are involved in not only the initiation but also the persistence of pathologic pain by directly activating nociceptive sensory neurons [105]. Another main focal point were genes associated with immune regulatory processes including genes coding for interleukins (\( \text{IL1A, IL6, IL10, IL1B, IL1RN} \)) [106–109] and the histocompatibility complex related gene \( \text{HLA-DRB1} \) [110], which has been shown to be involved in immunological mechanisms of pain [111]. This is also supported by published evidence for the further genes in this list, such as \( \text{TNF} \) [112], \( \text{GCH1} \) [113], and \( \text{P2RX7} \) [114]. The view of pain and its development towards persistence as a trait resulting from alterations in the immune system is a concept that is biologically highly plausible and agrees with other lines of pain research and has been discussed more detailed in a previous work [115]. Another major process group included members of the transient receptor potential (TRP) family (\( \text{TRPA1, TRPM8, TRPV1} \)) that are expressed at nociceptors and which are well established players in the perception of pain [116]. This similarly applies to the Toll-like receptor genes (\( \text{TLR4 and TLR9} \)), which have been associated with the inflammatory consequences of glia activation (including microglia and astrocytes), sensory neurons, and other cell types which can influence nociceptive processing [47].

3.1.3. Functional Involvement of Detected Variants

In the present study sample, a total of 691 genetic coding variants were found. Regardless of the sample preselection, 68 clinical associations, of which 29 have associated with various painful conditions (Table 2), could be queried for the observed variants from open access data sources. These comprise: (i) the Online Mendelian Inheritance in Man (OMIM®) database (https://www.omim.org), (ii) the NCBI gene index database, the GeneCards database (https://www.genecards.org) and the 1000 Genomes Browser (all accessed in October 2020). Although the present gene set has been assembled with a focus of a relevance to pain, many of its members have been implicated in pharmacogenetic modulations of drug effects (Table 3). Moreover, several of the genes in the present NGS panel have been chosen as targets of analgesics, approved or under current clinical development (data not shown). Functional polymorphisms that have been proven to influence gene functions are the most common candidate mutations in human that play a vital role in the genetic basis of certain diseases [111,117].
Table 2. Variants with reported clinical effects. The table provides a list of human variants in the 72 putative chronic pain genes which were found in the present random sample of 61 subjects of Caucasian ethnicity, for which clinical associations have been reported.

| Gene Name | Variant        | DbSNP * Accession Number | Consequence     | Known Clinical Association                                      | Reference |
|-----------|----------------|--------------------------|-----------------|-----------------------------------------------------------------|-----------|
| ACAN      | chr15:g.89398553C>A rs35430524 NON_SYNONYMOUS | Chronic low back pain | [49]             |                                                                 |           |
| ACAN      | chr15:g.89402051A>G rs1042630 NON_SYNONYMOUS | Chronic low back pain | [49]             |                                                                 |           |
| ADRB2     | chr5:g.142780339C>A rs1042718 NON_SYNONYMOUS | Associated with increased response to fentanyl | [118]           |                                                                 |           |
| ADRB2     | chr5:g.148206917C>T rs1042719 SYNONYMOUS | Associated with chronic pain in sickle cell disease | [119]           |                                                                 |           |
| COMT      | chr22:g.19951207C>T rs4818 SYNONYMOUS | Associated with chronic pain in sickle cell disease | [119]           |                                                                 |           |
| ESR1      | chr6:g.152420095G>A rs2228480 SYNONYMOUS | Chronic post-surgical pain | [120]           | Risk of knee osteoarthritis | [121]   |
| HTR2A     | chr13:g.474909234T>G rs6314 NON_SYNONYMOUS | Development of rheumatoid arthritis | [122]           |                                                                 |           |
| IL1RN     | chr2:g.113887207T>C rs419598 SYNONYMOUS | Altered pain perception | [123]           | Knee osteoarthritis | [124] |
| IL1RN     | chr2:g.113890347T->C rs315952 SYNONYMOUS | Osteoarthritis | [125]           |                                                                 |           |
| IL6       | chr7:g.22771039G>T rs13306435 SYNONYMOUS | Associated with persistent lumbar radicular pain | [126]           | Pain variability | [127] |
| KCNS1     | chr20:g.43723627T>C rs734784 NON_SYNONYMOUS | Genotype GT is associated with Pain Insensitivity, Congenital as compared to genotype TT | [134]           | Pain Insensitivity | [135] |
| MTRR      | chr5:g.78859359A>G rs162036 NON_SYNONYMOUS | Associated with migraine | [128]           | Regulate the onset of gouty arthritis | [139] |
| P2RX7     | chr12:g.121592689T>C rs17525809 NON_SYNONYMOUS | Pain tolerance | [130]           |                                                                 |           |
| P2RX7     | chr12:g.121600253T>C rs208294 NON_SYNONYMOUS | Cold and heat pain sensitivity | [131]           | Cold pain sensitivity and analgesic effect of fentanyl | [132] |
| P2RX7     | chr12:g.121615103G>A rs1718119 NON_SYNONYMOUS | Relevance to diabetic neuropathic pain | [139]           |                                                                 |           |
| P2RX7     | chr12:g.121622304A>G rs3751143 NON_SYNONYMOUS | Oxaliplatin induced neuropathy | [133]           |                                                                 |           |
| SCN9A     | chr2:g.167141109G>C rs41268673 NON_SYNONYMOUS | Genotype GT is associated with Pain Insensitivity, Congenital as compared to genotype TT | [134]           | Pain Insensitivity | [135] |
| TRPA1     | chr8:g.72975801T>C rs7819749 SYNONYMOUS | Painful bladder syndrome | [135]           | Insensitivity to pain and erythromelalgia | [136] |
| TRPM8     | chr2:g.23485450G>A rs11562975 NON_SYNONYMOUS | Sensitivity to heat stimuli and topically applied capsaicin | [16]             |                                                                 |           |
| TRPV1     | chr17:g.3494361G>T rs222748 NON_SYNONYMOUS | Attenuated cold pain sensation | [137]           |                                                                 |           |
| TRPV1     | chr17:g.3494361G>T rs222748 NON_SYNONYMOUS | Burning pain and capsaicin sensitivity | [138]           |                                                                 |           |
| TRPV1     | chr17:g.3495374G>A rs222749 NON_SYNONYMOUS | Chronic migraine | [55]             | Altered pain perception | [140] |

**Pain Related**
| Gene Name | Variant | DbSNP # Accession Number | Consequence | Known Clinical Association | Reference |
|-----------|---------|--------------------------|-------------|----------------------------|-----------|
| **Non-Pain Related** | | | | | |
| ACAN      | chr15:g.89398407C>T | rs3743398 | NON_SYNONYMOUS | Glioblastoma multiforme | [141] |
| ACE       | chr17:g.61564052A>G | rs4331 | NON_SYNONYMOUS | Risk of late-onset Alzheimer’s disease | [142] |
| CASP9     | chr1:g.15833506C>T | rs2308950 | NON_SYNONYMOUS | Risk of non-Hodgkin’s lymphoma | [143] |
| CASP9     | chr1:g.15834360A>G | rs2020902 | SPLICE_SITE | Predisposition to lung cancer | [144] |
| CCR2      | chr3:g.46399174G>T | rs3918367 | NON_SYNONYMOUS | Bladder cancer risk | [145] |
| CCR2      | chr3:g.46399208G>A | rs1799864 | NON_SYNONYMOUS | Associated with endothelial function in prediabetic individuals | [146] |
| CCR2      | chr3:g.46399798T>C | rs1799865 | NON_SYNONYMOUS | Associated with prostatic hyperplasia and prostate cancer | [147] |
| CD4       | chr12:g.6924109C>T | rs11575099 | NON_SYNONYMOUS | Involved in multiple sclerosis | [148] |
| CFTR      | chr7:g.117175372A>G | rs121909046 | NON_SYNONYMOUS | Stressful life events and suicide | [149] |
| CFTR      | chr7:g.11719709G>C | rs1800095 | NON_SYNONYMOUS | Associated with idiopathic pancreatitis | [150] |
| CFTR      | chr7:g.11723505T>A | rs1042077 | NON_SYNONYMOUS | Associated with cystic fibrosis | [151] |
| ESR1      | chr6:g.152129308G>A | rs746432 | NON_SYNONYMOUS | Breast cancer risk | [152] |
| HTR2A     | chr13:g.47409034G>A | rs6314 | NON_SYNONYMOUS | Major depressive disorder | [153] |
| HTR2A     | chr13:g.47409149T>A | rs35224115 | NON_SYNONYMOUS | Obsessive-compulsive disorder | [154] |
| HTR2A     | chr13:g.47466222G>A | rs6305 | NON_SYNONYMOUS | Schizophrenia | [155] |
| IL1RN     | chr2:g.113877713A>C | rs879972 | SPLICE_SITE | Prostate cancer risk | [156] |
| IL6       | chr7:g.22771156C>G | rs2069849 | NON_SYNONYMOUS | Associated with obesity | [157] |
| MTRR      | chr5:g.7878424T>A | rs2303080 | NON_SYNONYMOUS | Risk of spinal cord injury and neurological deficits | [158] |
| MTRR      | chr5:g.7889216G>A | rs2287779 | NON_SYNONYMOUS | Risk of childhood acute lymphoblastic leukemia | [159] |
| NR3C1     | chr5:g.142661490A>G | rs6196 | NON_SYNONYMOUS | Gastric cancer risk | [160] |
| NR3C1     | chr5:g.142662280G>T | rs258751 | NON_SYNONYMOUS | Associated with corticosteroid dependency and resistance | [161] |
| NR3C1     | chr5:g.142779317T>A | rs56149945 | NON_SYNONYMOUS | Associated with high-altitude pulmonary edema | [162] |
| NR3C1     | chr5:g.142780337C>G | rs6190 | NON_SYNONYMOUS | Associated with cocaine use | [163] |
| NR3C1     | chr5:g.142780339C>A | rs6189 | NON_SYNONYMOUS | Associated with mood and anxiety disorders in patients with asthma | [164] |
| P2RX7     | chr12:g.121600238G>T | rs28360447 | STOP_GAINED | Osteoporosis risk | [165] |
Table 2. Cont.

| Gene Name | Variant | DbSNP Accession Number | Consequence | Known Clinical Association | Reference |
|-----------|---------|------------------------|-------------|----------------------------|-----------|
| PGR       | chr11:g.100909991T>C | rs500760 | SYNONYMOUS | Gastric cancer risk | [168] |
| PGR       | chr11:g.100922202G>A | rs1042839 | SYNONYMOUS | Sporadic neuroendocrine tumor risk | [169] |
| PRKCA     | chr17:g.64685078G>A | rs2227857 | SYNONYMOUS | Deep vein thrombosis | [170] |
| POMC      | chr2:g.25387624G>A | rs8192605 | SYNONYMOUS | Associated with substance dependence and body mass index | [171] |
| SERPINA6  | chr14:g.94772504G>A | rs1042394 | SYNONYMOUS | Associated with stress fractures | [172] |
| SERPINA6  | chr14:g.94776221A>C | rs2228541 | NON_SYNONYMOUS | Lymphoblastic leukemia | [173] |
| TLR4      | chr9:g.120475302A>T | rs4986790 | NON_SYNONYMOUS | Higher risk for gastric cancer | [174] |
| TLR4      | chr9:g.120475602C>T | rs4986791 | NON_SYNONYMOUS | Associated with lower respiratory tract infections | [175] |
| TRPM8     | chr2:g.234905078C>A | rs11563208 | SYNONYMOUS | Associated with cold-induced airway hyperresponsiveness in bronchial asthma | [176] |
| TRPV1     | chr17:g.3495391T>C | rs55916885 | NON_SYNONYMOUS | Associated with asthma | [177] |

<https://www.ncbi.nlm.nih.gov/snp/?cmd=search.

Table 3. Gene variants with reported pharmacogenetic effects. The table provides a summary of variants in genes included in the proposed panel of n = 72 genes and found in the DNA of the 61 analyzed subjects, that have been implicated in a pharmacogenetic context to modulate the effects of drugs administered for the treatment of pain or as disease modifying therapeutics in a painful disease.

| Gene Name | Variant | Affected Drug | Findings | Reference |
|-----------|---------|---------------|----------|-----------|
| ADRA2A    | rs1800545 | Oxycodone     | Allele A is associated with dose of opioids in people with Pain as compared to allele G in the development sample | [178] |
| ADRA2A    | rs11195419 | Oxycodone     | Allele A is associated with dose of opioids in people with Pain as compared to allele G in the development sample | [178] |
| ADRB2     | rs1042718 | Fentanyl      | Genotype AC is associated with increased response to fentanyl in healthy individuals as compared to genotype CC | [118] |
| CALCA     | rs3781719 | Botulinum     | Patients with the AA genotype and chronic migraine may have an increased response to botulinum toxin A as compared to patients with the AG or GG genotypes. Nominal association of this SNP with association of rheumatoid arthritis risk alleles | [55] |
| CCL21     | rs2812378 | Infliximab    | Allele T is associated with increased response to adalimumab in people with Arthritis | [179] |
| CD40      | rs1126535 | Adalimumab    | Patients with the CC genotype may be more likely to require postoperative intervention with opioids after adentonsillectomy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient’s requirement for pain management. Polymorphism is associated with decreased likelihood of headache disorders | [180] |
| COMT      | rs4633   | Morphine      | Allele A is associated with dose of opioids in people with Pain as compared to allele G in the development sample | [181] |
| DRD2      | rs6275   | Heroine       | Patients with the AA genotype may experience greater response to leflunomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to leflunomide, particularly rs2234693. | [182] |
| ESR1      | rs9340799 | Leflunomide   | Allele A is associated with dose of opioids in people with Pain as compared to allele G in the development sample | [183] |
Table 3. Cont.

| Gene Name | Variant | Affected Drug | Findings | Reference |
|-----------|---------|---------------|----------|-----------|
| IFNG      | rs2069705 | Etanercept    | Allele G is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis | [184] |
| IL1B      | rs1143634 | Morphine      | Allele A is associated with increased dose of morphine in women with Pain | [185] |
| IL6       | rs11265618 | Tocilizumab   | Patients with the CC genotype and rheumatoid arthritis may have a better response when treated with tocilizumab as compared to patients with the CT or TT genotype | [186] |
| MTRR      | rs1801394 | Folic Acid    | Female patients with the AA genotype and Migraine who are treated with folic acid and a vitamin b-complex may have decreased severity of pain as compared to patients with the GG genotype. | [187] |
| OPRM1     | rs1799971 | Opioids       | Allele G is associated with increased plasma concentrations of morphine in women with Pain, Postoperative as compared to allele A | [188] |
| P2RX7     | rs1718125 | Fentanyl      | Patients with the CC genotype may have decreased fentanyl dosage requirements as compared to patients with the CT or TT genotypes | [131] |
| PTGS2     | rs20417  | Ibuprofen     | Patients with the CC genotype may have decreased pain relief to ibuprofen as compared to patients with GG or CG genotype. | [189]; however, see [190] |

For example, a single nucleotide polymorphism determined as ER22/23EK (rs6189 and rs6190) is located in the exon 2 of the glucocorticoid receptor gene (NR3C1) and involves codons 22 and 23. This SNP is revered to be responsible for relative resistance to glucocorticoids [111] and is associated with several effects like mood and anxiety disorders in patients with asthma [191] and a more aggressive disease course in multiple sclerosis [111]. Results of a study of the functional consequences of P2RX7 polymorphisms in recombinant cells in vitro [132] suggested a correlation between gain-of-function and loss-of-function of P2RX7 expression. It was further demonstrated that in patients with diabetic peripheral neuropathic pain (DPNP), the presence of the gain-of-function SNPs rs208294 (His155Tyr) is associated with higher pain intensity scores. Another meta-analysis addressed the role of P2RX7 SNP (rs1718119) with the odds of Tuberculosis [192] and the findings indicate that this polymorphism could serve as a potential biological marker. Another recent study aimed to examine whether pharmacogenetics explains some of the variability in the response to fentanyl, which is an agonist of the µ-opioid receptor commonly used in the treatment of moderate-severe pain. Carriers of the C523A polymorphism (rs1042718) in the ADRB2 gene were associated with increased response to fentanyl [111].

3.1.4. Comparison to Other Proposals of Pain-Relevant Gene Assay Panels

The present panel for sequencing genes associated with pain complements alternative proposals, including commercial offerings of “pain gene” sets that promise to provide ready-to-use assays for private testing or clinical association studies. For example, the company GX Sciences (Austin, TX, US) advertises a panel containing 30 single nucleotide polymorphisms in 28 different genes that comes with a do-it-yourself saliva swab test kit. All genes have a referenced relationship to chronic pain, but no further insight into the gene selection criteria is provided, nor is there any further information on the genotyping method performed (https://www.gxsciences.com). This panel and the currently proposed one have only 8.3% of their total genes in common, while 42.8% of the GXS panel are so-called pain genes, i.e., genes mainly from the PainGenes database (http://www.jbldesign.com/jmogil/enter.html [7], with some extensions [8] comprising targets of approved analgesics [91] and genes known to be causally involved in familiarity syndromes with either absent or paroxysmal exaggerated pain [1]. For comparison, 65.3% of the presently proposed panel are “pain genes”.
Another alternative panel for sequencing pain-related genes is provided by Live Technologies (Carlsbad, CA, USA), the manufacturer of the Ion Torrent™ platform used for the present panel. It includes the complete exonic sequence of 64 pain-related genes. However, without further information on gene selection criteria (https://www.ampliseq.com). This set and the currently proposed set have only 11.5% of their total genes in common. However, 59.5% of this panel also belongs to the so-called “pain genes” mentioned above [8]. A third alternative is a cloud-based, publicly available knowledge base that enables virtual gene panels for human diseases and includes a virtual panel for chronic pain with 28 genes contributed by various departments, research groups, and consortia (https://panelapp.genomicsengland.co.uk). This set shares only 2% of the genes with the present panel, but 59.5% of its genes are also included in the “pain gene” set [8].

Thus, the present set of genes fits and complements other proposals. Taken above-mentioned proposals, the panel introduced in the present report and our previous panel [20] together, NGS sets for pain already cover 28.3% of the 540 genes included as references in the “pain-genes” set, which is based on the most stringent inclusion criteria by also requiring independent validations of a gene’s involvement in pain in knock-out models [7]. In contrast to the alternatives, the present set of pain-related genes is mainly based on a selection resulting from a computer-assisted functional genomic analysis [17]. According to a computational analysis of the functional involvement of the gene set [17], it covers > 70% of the genetic architecture of pain. This outperforms alternative proposals that purportedly single out pain-relevant genes but seem to lack a clear functional hypothesis. The apparent discrepancies between the different proposals, which also extend to the sets of pain-related genes used to complete the present panel, underscore that the genetic architecture of persistent pain is still incompletely understood and that several independent lines of research can be pursued, because combining all proposals into a large research panel is not yet an easily implemented option because of the technical limitations of NGS applications. The development of these panels is aimed at broadening the genetic perspective on pain. Indeed, although many candidate gene association studies have identified multiple genes relevant for pain phenotypes in the past decade, but roughly ten genes or gene complexes account for over half of the findings and several of these candidate gene associations have held up in replication [9].

3.2. Strengths and Limitations

The present AmpliSeq™ panel complements earlier proposals on genes relevant for pain and especially persistent pain [7,9,10,20] and provides a validated assay suitable for high-throughput analyses to further evaluate genetic biomarkers for pain in this clinical setting. The biological roles of the included genes are clearly defined by the functional-genomics description based on the current acquired knowledge about higher-level organization of gene products into biological pathways [193], of which the gold-standard is the Gene Ontology (GO) knowledge base [19]. These include a set of genes that have been shown to be essential for pain in a bioinformatics approach [17], which is in the present report regarded as the primary subset of major importance. Among the limitations, firstly, the selection of test persons does not reflect a random sample of a population, but only includes women with breast cancer. An attempt was made to reduce bias towards or against persistent pain by maintaining the respective ratio observed in the original cohort [94]. However, this proportion may not be identical for different settings of persistent pain. Furthermore, the inclusion of only women may have distorted the frequency of the X chromosome variant observed in this analysis.

It is important to emphasize that the present report is limited to the details of assay development including the gene selection process. The separate report of the panel development provides the details of its establishment and validation, along with the computational genomic bases of the gene selection and the functional implications of the selected gene set in the context of previous proposals of important genes related to persistent pain. Hence, it can be considered as a separate scientific analysis that would exceed the necessary ex-
planations provided within a genetic association report. In particular, the selection of the main subset of the present panel is based on a functional analysis and thus goes beyond the collection of genes discussed in the previous subsection, which seems to provide rather random collections based solely on mentions in the literature as pain-relevant genes.

In contrast, the genetic analyses for risk of persistent pain will be performed in a cohort of 70/70 women with persistent/non-persistent pain, extending a previous analysis [14]. After all, the immediate exploitation of the advanced technology which NGS provides over single variant analysis, which was still common a decade ago, is still easier to achieve in limited gene sets than in the whole genome due to technical limitations. In view of the high prevalence of chronic pain of about one fifth to one third of the European population [194,195], it is important to advance the discovery of genetic markers as quickly as possible.

4. Materials and Methods

4.1. Assembly of a Pain-Relevant Gene Set

The present NGS panel of pain relevant genes (Table 1) comprises two subsets derived (i) from a computational functional genomics bioinformatics approach to key players in the genetic architecture of pain [17] and (ii) further genes taken from independent proposals of published evidence-based genes relevant to (persistent) pain.

4.1.1. Computational Functional-Genomics Based Key Genes for Pain

The focus in the selection of genes was on maintaining, as completely as possible, the functional genomics picture of pain with a reduced number of genes, as had been achieved by applying the computational functional genomics-based method of reducing disease-related gene sets to their key components [17]. Thus, subset 1 (Table 1) of the presently proposed NGS panel consisted of the 29 genes with which it had been possible to reproduce the biological processes in which the full set of 540 pain-relevant genes is involved by over 70% although they represented only 5% of the original genes.

4.1.2. Published Evidence-Based Genes Relevant to Pain

In order to fully exploit the technical potential of the NGS panel, another 50 genes were added as subset 2 (Table 1). Specifically, these genes were selected based on intersections between two independently proposed alternative sets of human genes involved in modulating the risk or clinical course of pain and its persistence (Figure 1). The sets contained 127 genes [9] and 152 genes [10]. Their intersection included 50 genes. As subset 1 and subset 2 shared seven genes, the present NGS panel included 72 unique genes.

4.2. Establishment of the AmpliSeq™ NGS Panel

4.2.1. DNA Sample Acquisition

The present set of genes complements an earlier NGS panel [20], which was successfully applied to genotype versus phenotype associations in patients who had undergone breast cancer surgery [14]. The laboratory analyses were therefore performed on the same DNA samples that were used previously, but with a non-redundant technical implementation. The samples comprise a subset from a cohort of \( n = 1000 \) women with unilateral non-metastatic breast cancer, which has already been reported in connection with the development of persistent pain after surgery [21]. All subjects were of Caucasian ethnicity by self-assignment. The study followed the Declaration of Helsinki and was approved by the Coordinating Ethics Committee of the Helsinki University Hospital. Each participating subject provided informed written consent including into the study of pain-relevant genes.

For the present method-establishment and validation, a genetic association analysis with pain status was not intended. Nevertheless, in order to obtain a representative cohort for the evaluation of the frequency of genetic variants, which is as close as possible to a random sample of test subjects, the relative proportion of patients with persistent pain and without persistent pain, as observed in the entire cohort of 1000 women [94], was retained.
in the composition of the samples. Specifically, for assay establishment, 60 samples were planned. In the above-mentioned cohort, a total of 853 individuals were analyzed, 779 of whom had a favorable outcome with respect to pain, while 74 had developed persistent pain according to criteria defined in [94]. In 60 samples, this ratio corresponds to 5.7 individuals with persistent pain. After rounding, the sample currently analyzed consisted of 55 subjects without pain and six patients with persistent pain.

4.2.2. DNA Amplification

A multiplex PCR amplification strategy for the sequences of the coding genes was accomplished online (Ion Ampliseq™ Designer; http://www.ampliseq.com) to amplify the target region specified above with 25 base pair exon padding. After a comparison of several primer design options, the design providing the maximum target sequence coverage was chosen. The 403kb target-sized panel has been ordered with 1504 amplicons and covered approximately 97.54% of the target sequence. A total of 10 ng DNA per sample was used for the target enrichment by a multiplex PCR and each DNA pool was amplified with the Ion Ampliseq™ Library Kit in conjunction with the Ion Ampliseq™ “custom Primer Pool”-protocols according to the manufacturer procedures (Life Technologies, Darmstadt, Germany).

After each pool had undergone 17 PCR cycles, the PCR primers were removed with FuPa Reagent (Thermo Fisher Scientific, Dreieich, Germany) and the amplicons were ligated to the sequencing adaptors with short stretches of index sequences (barcodes) that enabled sample multiplexing for subsequent steps (Ion Xpress™ Barcode Adapters Kit; Life Technologies, Carlsbad, CA, USA). After purification with APMure XP beads (Beckman Coulter, Krefeld, Germany), the barcoded libraries were quantified with a Qubit® 2.0 Fluorimeter (Life Technologies, Darmstadt, Germany) and normalized for DNA concentration to a final concentration of 20 pmol/L using the Ion Library Equalizer™ Kit (Life Technologies, Darmstadt, Germany). Equalized barcoded libraries from 9–10 samples at a time were pooled. To clonally amplify the library DNA onto the Ion Sphere Particles (ISPs; Life Technologies, Darmstadt, Germany), the library pool was subjected to emulsion PCR by using an Ion PGM HI-Q View Template Kit on an PGM OneTouch system (Life Technologies, Darmstadt, Germany) following the manufacturer’s protocol.

4.2.3. DNA Sequencing

Enriched ISPs which carried many copies of the same DNA fragment were subjected to sequencing on an Ion 318 Chip to sequence-pooled libraries with 9 to 10 samples. The number of combined libraries that can be accommodated in a single sequencing run depends on the size of the chip, the balance of barcoded library concentration, and the coverage required. The high-capacity 318 chip was chosen (instead of the low-capacity 314 or the medium-capacity 316 chip) to obtain a high sequencing depth of coverage of minimum 30 x. Sequencing was performed using the sequencing kit (Ion PGM HI-Q Sequencing Kit; Life Technologies, Darmstadt, Germany) as per the manufacturer’s instructions with the 200 bp single-end run configuration. This kit contained the most advanced sequencing chemistry available to users of the Ion PGM System (Life Technologies, Darmstadt, Germany).

4.2.4. Assay Validation

The current Ampliseq™ panel is technically identical to the panel which established previously [20], which had been validated by external Sanger sequencing. Hence, no divergences in the current panel were expected. Again, for method validation a genomic region from the COMT gene which has already been in focus in a previous study [196], was chosen for validation by Sanger sequencing [197,198] in an independent external laboratory (Eurofins Genomics, Ebersberg, Germany), which was performed in ten DNA samples randomly chosen from the n = 72 samples in the present cohort. Amplification of the respective DNA segments was done using PCR primer pairs (forward, re-
verse) of (i) 5′-CCTTATCGGCTGGAACGAGTT-3′, 5′-GTAAGGGCTTTGATGCCTGGT-3′ (ii) 5′-GTTATTCCTCTGTAAGCAGCTGCCT-3′, 5′-TGTTTGTTTTAGATTGTGGTGGT-3′ (iii) 5′-TTTATTGCAAGACTTGCGGGTGTC-3′, 5′-AGCCTTTTGAGAGATTTGAGTTTCA-3′. The results of Sanger sequencing were aligned with the genomic sequence and analyzed using Chromas Lite® (Version 2.1.1, Technelysium Pty Ltd., South Brisbane, Australia) and the GenomeBrowse® (Version 2.0.4, Golden Helix, Bozeman, MT, USA) was used to compare the sequences obtained with NGS or Sanger techniques.

4.3. Data Analysis

4.3.1. Bioinformatics Generation of Sequence Information

The raw data (unmapped BAM-files) from the sequencing runs were processed using Torrent Suite Software (Version 5.2.2, Life Technologies, Darmstadt, Germany) to generate read alignments which are filtered by the software into mapped BAM-files using the reference genomic sequence (hg19) of target genes. Variant calling was performed with the Torrent Variant Caller Plugin using as key parameters: minimum allele frequency = 0.15, minimum quality = 10, minimum coverage = 20 and minimum coverage on either strand = 3. The annotation of called variants was done using the Ion Reporter Software (Version 4.4; Life Technologies, Darmstadt, Germany) for the VCF files that contained the nucleotide reads and the SNP & Variation Suite® (SVS) software (Version 8.9.0 for Linux, Golden Helix, Bozeman, MT, USA) to map the sequences to the reference sequences GRCh37 hg19 (dated February 2009). The SNP and Variation Suite software (SVS Version 8.4.4; Golden Helix, Bozeman, MT, USA) was used for the analysis of sequence quality and coverage.

4.3.2. Descriptive Analysis of Variant Frequencies

Variants were identified and assigned to coding, regulatory, intronic or other locations on the genes using the SVS software. Based on the observed allelic frequency, the expected number of homozygous and heterozygous carriers of the respective SNP (single nucleotide polymorphism) according to the Hardy-Weinberg equilibrium was compared with the observed number using Fisher’s exact test [199] as proposed previously [200]. Only variants within the Hardy–Weinberg equilibrium were retained. The number of variants detected was analyzed for correlation with gene length, i.e., the number of nucleotides read for each gene in the present assays. A robust correlation analysis was performed by calculating the percentage bend correlation coefficient using the R-package “WRS2” (https://cran.r-project.org/package=WRS2 [201]). Since the introns were considered only at their edges and intergenic regions only when the primer localization suggested by the panel design software included them, the correlation analysis was repeated for the exonic variants only. In order to recheck the correspondence of the read number of nucleotides with independent information about the length of the respective genes, the latter was retrieved from the Bioconductor Annotation Data Package “org.Hs.eg.db” (https://bioconductor.org/packages/release/data/annotation/html/org.Hs.eg.db.html [202]) using the R library “EDASeq” (https://bioconductor.org/packages/release/bioc/html/EDASeq.html [203]).

4.3.3. Identification of the Functional Genomics Biological Roles of the Set of Pain Genes

The approach to the functional genomics biological roles of the set of pain genes was the same as before for the complete set of pain genes [8,17], or for other contextually selected sets of genes relevant to pain [115]. The methods were described in detail in special publications [17,98]. The biological roles of the set of the \( n = 72 \) genes of the present panel, versus the biological roles of all human genes, were retrieved via analyses of the Gene Ontology knowledge base (GO; http://www.geneontology.org/) [204,205]. In the GO, knowledge of the biological processes, molecular functions and cellular components of genes is formulated using a controlled and clearly defined vocabulary of GO terms annotated to the genes [8,98]. Here, the biological processes were used to compare the results with previous reports that had used this GO category [8,98]. In the GO, the terms are related by “is-a”, “part-of” and “regulated” relationships and form a polyhierarchy
organized in a directed acyclic graph (DAG [97]), with a top-down polyhierarchy starting with more general root terms and specializing in the leaves representing GO terms of narrowest definitions.

In order to obtain the DAG describing the biological processes in which the 72 selected genes are involved, an overrepresentation analysis (ORA) was performed, which compared the occurrence of the specific set of genes annotated to certain GO terms with the expected occurrence of all human genes to these terms. The significance of a GO term associated with the present set of genes was determined using Fisher’s exact tests [199] with a $p$-value threshold of $p < 5 \times 10^{-15}$ and an $\alpha$ correction for multiple testing according to Bonferroni [206]. The conservative thresholds were chosen heuristically, with the criterion that the number of significant GO terms should not exceed the size of the gene set. The analyses were performed using our R library “dbtORA” ([https://github.com/IME-TMP-FFM/dbtORA [100]]) on the R software environment (version 4.0.2 for Linux, country; http://CRAN.R-project.org/ [92]).

In order to obtain an understandable interpretation of the GO-based functional genomics of pain covered by the selected NGS panel of 72 genes, the information was further reduced. As a basis for the selection of the most appropriate terms to describe the DAG, i.e., the terms that can serve as headlines for each branch of the DAG, the remarkableness measure was previously introduced [98]. That is, for each term $T_i$ in the set of terms, its remarkableness, $Rem(T_i)$, was calculated as the product of certainty and information value, i.e., $Rem(T_i) = Cert(T_i) \cdot Info(T_i)$. There, the certainty of a term $T_i$ in the significant term set resulting from the ORA, is defined as $Cert(T_i) = p$ (there is a Term with smaller $p$-value) $= \left\{ \{T_k : p - value(T_k) < p - value(T_i)\} \right\} / n_T$, where $n_T$ denotes the number of significant GO terms annotated to the given set of genes. This reflects how safe it is to assume that the term $T_i$ describes the gene set, with numerical values in the interval $[0,1]$. The information value of the term $T_i$ can be captured using the (partial) Shannon information calculated as $Info(T_i) = -e \cdot p_i \cdot \ln(p_i)$ with $p_i = n_G(T_i)/n_G$, where $n_G(T_i)$ is the number of genes in the input set annotated to term $T_i$ and $n_G$ is the number of all genes in the set. By using the factor $e$ and the natural logarithm the values of the information are normalized to the interval $[0,1)$.

In each branch of the DAG, the most remarkable term qualified as a potential heading, i.e., GO terms that succinctly summarize the biological processes covered by the branch of the polyhierarchy in which they represent the most remarkable term. Of the GO terms that lend themselves to being headlines, the most important subset was identified using an item categorization technique implemented as computed ABC analysis, which meets the basic requirements of feature selection using filtering techniques [207]. ABC analysis aims to divide a data set into three disjoint subsets named “A”, “B”, and “C”. Set “A” should contain the “important few” elements, i.e., those elements that make it possible to achieve maximum yield with minimum effort [208]. Sets “B” and “C” include elements where an increase in expenditure is proportional to an increase in yield or the “trivial many”, respectively. Hence, GO terms that were members of ABC set “A” were retained as most significant to the functional genomics covered by the 72 genes in the present NGS panel. The calculations were performed using the R package “ABCanalysis” ([https://cran.r-project.org/package=ABCanalysis [99]]). As this provided still many GO terms, a more global abstraction was obtained by applying the method of “subsumption” as introduced previously in the context of functional abstraction as a method to discover knowledge in gene ontologies [98]. That is, let $T$ be a term in a specific ontology which covers the terms $T_1, \ldots, T_k$. A set of headlines $H$ containing $T_1, \ldots, T_k$ is abstracted if $T_1, \ldots, T_k$ are replaced by $T$ in $H$, thereby reducing the number of headlines. This aimed for a 5–9 final terms describing the polyhierarchy, which would ideally be within Miller’s optimum of a human understandable size of a set of objects [209].
5. Conclusions

A 72-pain gene NGS panel is proposed that covers (i) a subset of 29 genes identified previously in a bioinformatics approach as key genes covering the biological functions of 540 genes relevant to pain by 70% [17]. Additional genes that were included, had been independently proposed as relevant for persistent pain [9,10], and the functional focus of the whole panel was now on immune or inflammatory processes, in line with the increasing evidence that such processes are key players in persistent pain [115]. Together with a recently established AmpliSeq™ panel of 77 further pain-relevant genes [20], the assay covers a relevant part of the current state of knowledge on the genetic architecture of persistent pain (Figure 1). The assay is applicable for small to large-scale experimental setups to access information about any nucleotide within the coding and regulatory portions of pain-relevant genes in a study cohort at costs per raw megabase which are in line with contemporary genotyping costs across different technical methods of NGS. In the genotypes of the 61 subjects studied in the context of the present assay establishment, tens of variants were found that had previously been reported with functional implications for pain, pharmacogenetics of analgesics, and for pharmacological treatments not related to pain.

Author Contributions: Supervised the project and acquired funding: J.L.; conceived the experiments: J.L., D.K., and E.K.; designed the gene panel: D.K. and J.L.; performed the genotyping: D.K.; analyzed the data: J.L. and D.K.; interpretation of the results: D.K., J.L, E.K., and S.M.; wrote the paper: J.L., D.K., E.K., and S.M.; critical evaluation of the study results: S.M. and J.L.; provided DNA samples: E.K. All authors discussed the results and commented on the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This work has been funded by the European Union Seventh Framework Programme (FP7/2007–2013) under grant agreement no. 602919 (“GLORIA”, J.L.) and the Landesoffensive zur Entwicklung wissenschaftlich-ökonomischer Exzellenz (LOEWE), LOEWE-Zentrum für Translationale Medizin und Pharmakologie (J.L.). These public funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Institutional Review Board Statement: Both the Coordinating Ethics Committee (journal number 136/E6/2006) and the Ethics Committee of the Department of Surgery (148/E6/05) of the Helsinki and Uusimaa Hospital District approved the study protocol.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The original data containing the patients’ genetic information cannot be shared due to data security restrictions.

Conflicts of Interest: The authors have declared that no further conflict of interest exist.

References

1. Lötsch, J.; Lippmann, C.; Kringel, D.; Uultsch, A. Integrated computational analysis of genes associated with human hereditary insensitivity to pain. A drug repurposing perspective. Front. Neurosci. 2017, 10, 252. [CrossRef] [PubMed]
2. Bennett, D.L.; Woods, C.G. Painful and painless channelopathies. Lancet Neurol. 2014, 13, 587–599. [CrossRef]
3. Mogil, J.S. The genetic mediation of individual differences in sensitivity to pain and its inhibition. Proc. Natl. Acad. Sci. USA 1999, 96, 7744–7751. [CrossRef] [PubMed]
4. Navratiłova, E.; Rau, J.; Oyarzo, J.; Tien, J.; Mackenzie, K.; Stratton, J.; Remeniuk, B.; Schwedt, T.; Anderson, T.; Dodick, D.; et al. CGRP-dependent and independent mechanisms of acute and persistent post-traumatic headache following mild traumatic brain injury in mice. Cephalalgia 2019, 39, 1762–1775. [CrossRef]
5. Lötsch, J.; Geisslinger, G.; Tegeder, I. Genetic modulation of the pharmacological treatment of pain. Pharm. Ther. 2009, 124, 168–184. [CrossRef]
6. Govil, M.; Mukhopadhyay, N.; Holverda, T.; Sluka, K.; Rakel, B.; Schutte, D.L. Effects of genotype on TENS effectiveness in controlling knee pain in persons with mild to moderate osteoarthritis. Eur. J. Pain 2020, 24, 398–412. [CrossRef]
7. Lacroix-Fralish, M.L.; Ledoux, J.B.; Mogil, J.S. The Pain Genes Database: An interactive web browser of pain-related transgenic knockout studies. Pain 2007, 131, 3.e1–3.e4. [CrossRef]
8. Lötsch, J.; Doehring, A.; Mogil, J.S.; Arndt, T.; Geisslinger, G.; Uultsch, A. Functional genomics of pain in analgesic drug development and therapy. Pharm. Ther. 2013, 139, 60–70. [CrossRef]
9. Mogil, J.S. Pain genetics: Past, present and future. *Trends Genet.* 2012, 28, 258–266. [CrossRef]
10. Zorina-Lichtenwalter, K.; Meloto, C.B.; Khoury, S.; Diatchenko, L. Genetic predictors of human chronic pain conditions. *Neuroscience* 2016, 338, 36–62. [CrossRef]
11. Doehring, A.; Küsenner, N.; Flühr, K.; Neddermeyer, T.J.; Schneider, G.; Lötsch, J. Effect sizes in experimental pain produced by gender, genetic variants and sensitzation procedures. *PLoS ONE* 2011, 6, e17724. [CrossRef] [PubMed]
12. Pasternak, G.W.; Inturrisi, C.E. Feeling pain? Who’s your daddy. *Nat. Med.* 2006, 12, 1243–1244. [CrossRef] [PubMed]
13. Mogil, J.S. Are we getting anywhere in human pain genetics? *Pain* 2009, 146, 231–232. [CrossRef] [PubMed]
14. Kringel, D.; Kaunisto, M.A.; Kalso, E.; Lötsch, J. Machine-learned analysis of the association of next-generation sequencing-based genotypes with persistent pain after breast cancer surgery. *Pain* 2019, 160, 2263–2277. [CrossRef] [PubMed]
15. Metzker, M.L. Sequencing technologies—the next generation. *Nat. Rev. Genet.* 2010, 11, 31–46. [CrossRef] [PubMed]
16. Kringel, D.; Geisslinger, G.; Resch, E.; Oertel, B.G.; Thrun, M.C.; Heinemann, S.; Lötsch, J. Machine-learned analysis of the association of next-generation sequencing based human TRPV1 and TRPA1 genotypes with the sensitivity to heat stimuli and topically applied capsaicin. *Pain* 2018, 159, 1366–1381. [CrossRef]
17. Lippmann, C.; Ultsch, A.; Lötsch, J. Computational functional genomics-based reduction of disease-related gene sets to their key components. *Bioinformatics* 2018. [CrossRef]
18. Harris, M.A.; Clark, J.; Ireland, A.; Lomax, J.; Ashburner, M.; Foulger, R.; Eilbeck, K.; Lewis, S.; Marshall, B.; Mungall, C.; et al. The Gene Ontology (GO) database and informatics resource. *Nucleic Acids Res.* 2004, 32, D258–D261. [CrossRef]
19. Ashburner, M.; Ball, C.A.; Blake, J.A.; Botstein, D.; Butler, H.; Cherry, J.M.; Davis, A.P.; Dolinski, K.; Dwight, S.S.; Eppig, J.T.; et al. Gene ontology: Tool for the unification of biology. *The Gene Ontology Consortium*. *Nat. Genet.* 2000, 25, 25–29. [CrossRef]
20. Kringel, D.; Kaunisto, M.A.; Lippmann, C.; Kalso, E.; Lötsch, J. Development of an AmpliSeq™ panel for next-generation sequencing of a set of genetic predictors of persistent pain. *Front. Pharmacol.* 2018, 9, 1008. [CrossRef] [PubMed]
21. Lüots, J.; Ultsch, A.; Kalso, E. Prediction of persistent post-surgery pain by preoperative cold pain sensitivity: Biomarker development with machine-learning-derived analysis. *Br. J. Anaesth.* 2017, 119, 821–829. [CrossRef] [PubMed]
22. Di Cesare Mannelli, L.; Micheli, L.; Crocetti, L.; Giovannoni, M.P.; Vergelli, C.; Ghelardini, C. a2 Adrenoceptor: A Target for Neuropathic Pain Treatment. *Mini Rev. Med. Chem.* 2017, 17, 95–107. [CrossRef]
23. Skouen, J.S.; Smith, A.J.; Warrington, N.M.; PB, O.S.; McKenzie, L.; Pennell, C.E.; Straker, L.M. Genetic variation in the beta-2 adrenergic receptor is associated with chronic musculoskeletal complaints in adolescents. *Eur. J. Pain (Lond. Engl.)* 2012, 16, 1232–1242. [CrossRef] [PubMed]
24. Kim, H.Y. Phospholipids: A neuroinflammation emerging target. *Nat. Chem. Biol.* 2015, 11, 99–100. [CrossRef] [PubMed]
25. Cameron, B.M.; VanderPutten, D.M.; Merrill, C.R. Preliminary study of an increase of a plasma apolipoprotein E variant associated with peripheral nerve damage. A finding in patients with chronic spinal pain. *Spine* 1995, 20, 581–589. [CrossRef] [PubMed]
26. Biber, K.; Boddeke, E. Neuronal CC chemokines: The distinct roles of CCL21 and CCL2 in neuropathic pain. *Front. Cell Neurosci.* 2014, 8, 210. [CrossRef] [PubMed]
27. Liou, J.T.; Lee, C.M.; Day, Y.J. The immune aspect in neuropathic pain: Role of chemokines. *Acta Anaesthesiol. Taiwan* 2013, 51, 127–132. [CrossRef] [PubMed]
28. Wu, X.B.; Jia, P.B.; Zhang, Z.L.; Cao, D.L.; Gao, M.H.; Jiang, B.C.; Gao, Y.J. Chemokine receptor CCR2 contributes to neuropathic pain and the associated depression via increasing NR2B-mediated currents in both D1 and D2 dopamine receptor-containing medium spiny neurons in the nucleus accumbens shell. *Neuropsychopharmacology* 2018, 43, 2230–2330. [CrossRef]
29. Noor, S.; Wilson, E.H. Role of C-C chemokine receptor type 7 and its ligands during neuroinflammation. *J. Neuroinflamm.* 2012, 9, 77. [CrossRef]
30. Addis, D.R.; DeBerry, J.J.; Aggarwal, S. Chronic Pain in HIV. *Mol. Pain* 2020, 16, 1744806920927276. [CrossRef]
31. Hendry, L.M.; Wadley, A.L.; Cherry, C.L.; Price, P.; Lombard, Z.; Kamerman, P.R. TNF Block Gene Variants Associate With Pain Intensity in Black Southern Africans With HIV-associated Sensory Neuropathy. *Clin. J. Pain* 2016, 32, 45–50. [CrossRef]
32. Yang, J.A.; He, J.M.; Lu, J.M.; Jie, L.J. Jun, Gal, Cd74, and C1qb as potential indicator for neuropathic pain. *J. Cell Biochem.* 2018, 119, 4792–4798. [CrossRef]
33. Huang, W.; Kabbani, N.; Brannan, T.K.; Lin, M.K.; Theiss, M.M.; Hamilton, J.F.; Ecklund, J.M.; Conley, Y.P.; Vodovotz, Y.; Brienza, D.; et al. Association of a Functional Polymorphism in the CHRFAM7A Gene with Inflammatory Response Mediators and Neuropathic Pain after Spinal Cord Injury. *J. Neurotrauma* 2019, 36, 3026–3033. [CrossRef]
34. Onojjighofia, T.; Meshkin, B.; Nguyen, S.V.; Schwartz, D.; Akindele, B. Perception of Analgesia in Narcotic Users with Chronic Pain: A Multi-Center Cross-Sectional Study Comparing Genotype to Pain VAS (P.A.I.N. Study). *Acta Anaesthesiol. Taiwan* 2013, 51, 47–53. [CrossRef] [PubMed]
35. Nah, S.S.; Lee, H.; Hong, Y.; Im, J.; Won, H.; Chang, S.H.; Kim, H.K.; Kwon, J.T.; Kim, H.J. Association between endothelin-1 and fibromyalgia syndrome. *Mol. Med. Rep.* 2017, 16, 6234–6239. [CrossRef]
36. Vergnolle, N. Modulation of visceral pain and inflammation by protease-activated receptors. *Br. J. Pharm.* 2004, 141, 1264–1274. [CrossRef]
37. Tsuda, M.; Masuda, T.; Kitano, J.; Shimoyama, H.; Tozaki-Saitoh, H.; Inoue, K. IFN-gamma receptor signaling mediates spinal microglia activation driving neuropathic pain. *Proc. Natl. Acad. Sci. USA* 2009, 106, 8032–8037. [CrossRef]
38. Loncar, Z.; Curić, G.; Mestrović, A.H.; Mičković, V.; Bilić, M. Do IL-1β and IL-1RN modulate chronic low back pain in patients with post-traumatic stress disorder? *Coll. Antropol.* 2013, 37, 1237–1244.
39. Shoskes, D.A.; Albakri, Q.; Thomas, K.; Cook, D. Cytokine polymorphisms in men with chronic prostatitis/chronic pelvic pain syndrome: Association with diagnosis and treatment response. J. Urol. 2002, 168, 331–335. [CrossRef]

40. Tsuda, M.; Tozaki-Saitoh, H.; Masuda, T.; Toyomitsu, E.; Iezuka, T.; Yamamoto, T.; Inoue, K. Lyn tyrosine kinase is required for P2X(4) receptor upregulation and neuropathic pain after peripheral nerve injury. Glia 2008, 56, 50–58. [CrossRef]

41. Qu, Y.J.; Jia, L.; Zhang, X.; Wei, H.; Yue, S.W. MAPK Pathways Are Involved in Neuropathic Pain in Rats with Chronic Compression of the Dorsal Root Ganglion. Evid. Based Complement. Altern. Med. 2016, 2016, 6153215. [CrossRef]

42. Lüösch, J.; Geisslinger, G. Are mu-opioid receptor polymorphisms important for clinical opioid therapy? Trends Mol. Med. 2005, 11, 82–89. [CrossRef]

43. Sorge, R.E.; Irang, T.; Dorfman, R.; Smith, S.B.; Beggs, S.; Ritchie, J.; Austin, J.S.; Zaykin, D.V.; Vander Meulen, H.; Costigan, M.; et al. Genetically determined P2X7 receptor pore formation regulates variability in chronic pain sensitivity. Nat. Med. 2012, 18, 595–599. [CrossRef]

44. Warner, S.C.; van Meurs, J.B.; Schiphof, D.; Bierma-Zeinstra, S.M.; Hofman, A.; Uitterlinden, A.G.; Richardson, H.; Jenkins, W.; Doherty, M.; Valdes, A.M. Genome-wide association scan of neuropathic pain symptoms post total joint replacement highlights a variant in the protein-kinase C gene. Eur. J. Hum. Genet. 2017, 25, 446–451. [CrossRef]

45. He, Y.; Wilkie, D.J.; Nazari, J.; Wang, R.; Messing, R.O.; DeSimone, J.; Molokie, R.E.; Wang, Z.J. PKCδ-targeted intervention relieves chronic pain in a murine sickle cell disease model. J. Clin. Investig. 2016, 126, 3053–3057. [CrossRef]

46. Hutchinson, M.R.; Zhang, Y.; Shridhar, M.; Evans, J.H.; Buchanan, M.M.; Zhao, T.S.; Slivka, P.F.; Coats, B.D.; Rezvani, N.; Wieseler, J.; et al. Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain Behav. Immun. 2010, 24, 83–95. [CrossRef]

47. Lacagnina, M.J.; Watkins, L.R.; Grace, P.M. Toll-like receptors and their role in persistent pain. PLoS ONE 2011, 7, e0181580. [CrossRef]

48. Leung, L.; Cahill, C.M. TNF-alpha and neuropathic pain—A review. J. Neuroinflamm. 2010, 7, 27. [CrossRef]

49. Perera, R.S.; Dissanayake, P.H.; Senarath, U.; Wijayaratne, L.S.; Dissanayake, V.H.W. Variants of ACAN are associated with severity of lumbar disc herniation in patients with chronic low back pain. PLoS ONE 2017, 12, e0181580. [CrossRef]

50. Shehab, D.K.; Al-Jarallah, K.F.; Al-Awadhi, A.M.; Al-Herz, A.; Nahar, I.; Haider, M.Z. Association of angiotensin-converting enzyme (ACE) gene insertion-deletion polymorphism with spondyloarthropathies. J. Biomed. Sci. 2008, 15, 61–67. [CrossRef]

51. Knisely, M.R.; Conley, Y.P.; Smoot, B.; Paul, S.M.; Levine, J.D.; Miaskowski, C. Associations between catecholaminergic and serotonergic genes and Persistent Arm Pain Severity Following Breast Cancer Surgery. J. Pain 2019, 20, 1100–1111. [CrossRef]

52. Kohli, U.; Muszkat, M.; Sofowora, G.G.; Harris, P.A.; Friedman, E.A.; Dupont, W.D.; Scheinin, M.; Wood, A.J.; Stein, C.M.; Kurnik, D. Effects of variation in the human alpha2A- and alpha2C-adrenoceptor genes on cognitive tasks and pain perception. Eur. J. Pain (Lond. Engl.) 2010, 14, 154–159. [CrossRef]

53. Choucair-Jaafar, N.; Yalcin, I.; Rodeau, J.L.; Waltisperger, E.; Freund-Mercier, M.J.; Barrot, M. Beta2-adrenoceptor agonists alleviate neuropathic allodynia in mice after chronic treatment. Br. J. Pharm. 2009, 158, 1683–1694. [CrossRef]

54. Vargas-Alarcon, G.; Fragoso, J.M.; Cruz-Robles, D.; Vargas, A.; Martinez, A.; Lao-Villadóniga, J.I.; García-Fructuoso, F.; Vallejo, M.; Martinez-Lavin, M. Association of adrenergic receptor gene polymorphisms with different fibromyalgia syndrome domains. Arthritis Rheum 2009, 60, 2169–2173. [CrossRef]

55. Moreno-Mayordomo, R.; Ruiz, M.; Pascual, J.; Gallego de la Sacristana, M.; Vidriales, I.; Sobrado, M.; Cernuda-Morollon, E.; Gago-Veiga, A.B.; Garcia-Azorin, D.; Telleria, J.J.; et al. CALCA and TRPV1 genes polymorphisms are related to a good outcome in female chronic migraine patients treated with OnabotulinumtoxinA. J. Headache Pain 2011, 12, 169. [CrossRef]

56. Guo, T.M.; Liu, M.; Zhang, Y.G.; Guo, W.T.; Wu, S.X. Association between Caspase-9 promoter region polymorphisms and discogenic low back pain. Connect. Tissue Res. 2011, 52, 133–138. [CrossRef]

57. Midha, S.; Khajuria, R.; Shastri, S.; Kabra, M.; Garg, P.K. Idiopathic chronic pancreatitis in India: Phenotypic characterisation and strong genetic susceptibility due to SPINK1 and CFTR gene mutations. Gut 2010, 59, 800–807. [CrossRef]

58. Linnstaedt, S.D.; Bortsov, A.V.; Soward, A.C.; Svor, R.; Peak, D.A.; Jones, J.; Rathlev, N.; Lee, D.C.; Domeier, R.; Hendy, P.L.; et al. CRHBP polymorphisms predict chronic pain development following motor vehicle collision. Pain 2016, 157, 273–279. [CrossRef]

59. Sadeghiyeh, T.; Hosseini Biouki, F.; Mazaheri, M.; Zare-Shehneh, M.; Neamat zadeh, H.; Poursharif, Z. Association between Catechol-O-Methyltransferase Val158Met (158G/A) Polymorphism and Suicide Susceptibility: A Meta-analysis. J. Res. Health Sci. 2017, 17, e00383. [CrossRef]

60. Buskila, D.; Cohen, H.; Neumann, L.; Ebstein, R.P. An association between fibromyalgia and the dopamine D4 receptor exon III repeat polymorphism and relationship to novelty seeking personality traits. Mol. Psychiatry 2004, 9, 730–731. [CrossRef]

61. Smith, S.B.; Reenilä, I.; Männistö, P.T.; Slade, G.D.; Maixner, W.; Diatchenko, L.; Nackley, A.G. Epistasis between polymorphisms in COMT, ESRI, and GCH1 influences COMT enzyme activity and pain. Pain 2014, 155, 2390–2399. [CrossRef]

62. Latremoliere, A.; Costigan, M. GCH1, BH4 and pain. Curr. Pharm. Biotechnol. 2011, 12, 1728–1741. [CrossRef]

63. Huang, X.; Zhang, W.; Shao, Z. Association between GDFS rs143383 genetic polymorphism and musculoskeletal degenerative diseases susceptibility: A meta-analysis. BMC Med. Genet. 2018, 19, 169. [CrossRef]

64. Shiba, H.F.; El-Ghamrawy, M.K.; Shaheen, I.A.; Ali, R.A.; Mousa, S.M. Glutathione S-transferase gene polymorphisms (GSTM1, GSTT1, and GSTP1) in Egyptian pediatric patients with sickle cell disease. Pediatr. Dev. Pathol. 2014, 17, 265–270. [CrossRef]
65. Dominguez, C.A.; Kalliomäki, M.; Gunnarsson, U.; Moen, A.; Sandblom, G.; Kockum, I.; Lavant, E.; Olsson, T.; Nyberg, F.; Rygh, L.J.; et al. The DQB1 *03:02 HLA haplotype is associated with increased risk of chronic pain after inguinal hernia surgery and lumbar disc herniation. Pain 2013, 154, 427–433. [CrossRef]

66. Yildiz, S.H.; Ula¸sli, A.M.; Özdemir Erdoğan, M.; Dikici, O.; Arıkan Terzi, E.S.; Dündar, Ü.; Solak, M. Assessment of Pain Sensitivity in Patients With Chronic Low Back Pain and Association With HTR2A Gene Polymorphism. Arch. Rheumatol. 2017, 32, 3–9. [CrossRef]

67. Hu, X.; Jhun, E.H.; Yao, Y.; He, Y.; Molokie, R.E.; Wilkie, D.J.; Wang, Z.J. IL1A rs1800857 associates with chronic noncrescine pain in sickle cell disease. Pharmacogenomics 2016, 17, 1999–2006. [CrossRef]

68. Shao, Q.; Li, Y.; Wang, Q.; Zhao, J. IL-10 and IL-1β mediate neuropathic-pain-like behavior in the ventrolateral orbital cortex. Neurochem. Res. 2015, 40, 733–739. [CrossRef]

69. Attur, M.; Zhou, H.; Samuels, J.; Krasnokutsky, S.; Yau, M.; Scher, J.U.; Doherty, M.; Wilson, A.G.; Bencardino, J.; Hochberg, M.; et al. Interleukin 1 receptor antagonist (IL1RN) gene variants predict radiographic severity of knee osteoarthritis and risk of incident pain. Ann. Rheum. Dis. 2020, 79, 400–407. [CrossRef]

70. Ha, H.; Debnath, B.; Neamati, N. Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases. Theranostics 2017, 7, 1543–1588. [CrossRef]

71. Costigan, M.; Belfer, I.; Griffin, R.S.; Dai, F.; Barrett, L.B.; Coppola, G.; Wu, T.; Kiselycznyk, C.; Poddar, M.; Lu, Y.; et al. Multiple chronic pain states are associated with a common amino acid-changing allele in KCNS1. Brain 2010, 133, 2519–2527. [CrossRef]

72. Filic, V.; Vladic, A.; Stufilj, J.; Cicin-Sain, L.; Bailja, M.; Sucic, Z.; Jernej, B. Monoamine oxidases A and B gene polymorphisms in migraine patients. J. Neurol. Sci. 2015, 248, 149–153. [CrossRef]

73. Cai, M.; Hruby, V.J. The Melanocortin Receptor System: A Target for Multiple Degenerative Diseases. Curr Protein Pept Sci 2016, 17, 488–496. [CrossRef]

74. Sutherland, H.G.; Hermile, H.; Sanche, R.; Menon, S.; Lea, R.A.; Haupt, L.M.; Griffiths, L.R. Association study of MTHFD1 coding polymorphisms R134K and R653Q with migraine susceptibility. Headache 2014, 54, 1506–1514. [CrossRef]

75. González-Mercado, M.G.; Rivas, F.; Gallegos-Arecola, M.P.; Morán-Moguel, M.C.; Salazar-Páramo, M.; González-López, L.; Gámez-Nava, J.I.; Muñoz-Valle, J.F.; Medina-Coss, Y.L.R.; González-Mercado, A.; et al. TTR, RFC1, and MTHFR C677T and A1298C Polymorphisms and Disease Activity in Mexicans with Rheumatoid Arthritis Treated with Methotrexate. Genet. Test. Mol. Biomark. 2017, 21, 698–704. [CrossRef]

76. Tang, H.; Cheng, Z.; Ma, W.; Liu, Y.; Tong, Z.; Sun, R.; Liu, H. TLR10 and NFKBIA contributed to the risk of hip osteoarthritis: a Systematic evaluation based on Han Chinese population. Sci. Rep. 2018, 8, 10243. [CrossRef]

77. Jhun, E.H.; Sadhu, N.; Yao, Y.; He, Y.; Molokie, R.E.; Wilkie, D.J.; Wang, Z.J. Glucocorticoid receptor single nucleotide polymorphisms are associated with acute crisis pain in sickle cell disease. Pharmacogenomics 2018, 19, 1003–1011. [CrossRef]

78. Palmiriotta, R.; Barbanti, P.; Ialongo, C.; De Marchis, M.L.; Alessandroni, J.; Egeo, G.; Aurilia, C.; Fofi, L.; Valente, M.G.; Ferroni, P.; et al. Progesterone receptor gene (PROGINS) polymorphism correlates with late onset of migraine. Dyn. Cell Biol. 2015, 34, 208–212. [CrossRef]

79. Shenoda, B.B.; Alexander, G.M.; Ajit, S.K. Hsa-miR-34a mediated repression of corticotrophin releasing hormone receptor 1 regulates pro-opiomelanocortin in patients with complex regional pain syndrome. J. Transl. Med. 2016, 14, 64. [CrossRef]

80. Giefer, M.J.; Lowe, M.E.; Werlin, S.L.; Zimmerman, B.; Wilschanski, M.; Troendle, D.; Schwarzengger, S.J.; Pohl, F.J.; Palermo, J.; Ooi, C.Y.; et al. Early-Onset Acute Recurrent and Chronic Pancreatitis Is Associated with PRSS1 or CTRC Gene Mutations. J. Pediatr. 2017, 186, 95–100. [CrossRef]

81. Thorn, C.F.; Grosser, T.; Klein, T.E.; Altman, R.B. PharmGKB summary: Very important pharmacogene information for PTGS2. Theranostics 2011, 21, 607–613. [CrossRef] [PubMed]

82. Reimann, F.; Cox, J.J.; Belfer, I.; Diatchenko, L.; Zaykin, D.V.; McHale, D.P.; Drenth, J.P.; Dai, F.; Wheeler, J.; Sanders, F.; et al. Human SHMT inhibitors reveal defective glycine import as a targetable metabolic vulnerability of diffuse large B-cell lymphoma. Curr Protein Pept. Sci. 2015, 21, 607–613. [CrossRef] [PubMed]

83. Verbeeten, K.C.; Ahmet, A.H. The role of corticosteroid-binding globulin in the evaluation of adrenal insufficiency. J. Pediatr. Endocrinol. Metab. 2018, 31, 107–117. [PubMed]

84. Ducker, G.S.; Ghergurovich, J.M.; Mainolli, N.; Suri, V.; Jeong, S.K.; Hsin-Jung Li, S.; Friedman, A.; Manfredi, M.G.; Gitai, Z.; Kim, H.; et al. Human SHMT inhibitors reveal defective glycine import as a targetable metabolic vulnerability of diffuse large B-cell lymphoma. Proc. Natl. Acad. Sci. USA 2017, 114, 1104–1109. [CrossRef] [PubMed]

85. Liu, L.; Zhu, Y.; Noè, M.; Li, Q.; Pasricha, P.J. Neuronal Transforming Growth Factor beta Signaling via SMAD3 Contributes to Pain in Animal Models of Chronic Pancreatitis. Gastroenterology 2018, 154, 2252–2265.e2252. [CrossRef]

86. Schwartz, E.S.; Kim, H.Y.; Wang, J.; Lee, J.; Klann, E.; Chung, J.M.; Chung, K. Persistent pain is dependent on spinal mitochondrial antioxidative levels. J. Neurosci. 2009, 29, 159–168. [CrossRef]

87. Kiguchi, N.; Kobayashi, Y.; Saika, F.; Sakaguchi, H.; Maeda, T.; Kishioka, S. Peripheral interleukin-4 ameliorates inflammatory macrophage-dependent neuropathic pain. Pain 2015, 156, 684–693. [CrossRef]

88. Echeverry, S.; Shi, X.Q.; Haw, A.; Liu, H.; Zhang, Z.W.; Zhang, J. Transforming growth factor-beta1 impairs neuropathic pain through pleiotropic effects. Mol. Pain 2009, 5, 16. [CrossRef]
118. Saiz-Rodríguez, M.; Ochoa, D.; Herrero, C.; Belmonte, C.; Román, M.; Alday, E.; Koller, D.; Zubiaga, P.; Mejía, G.; Hernández-Martínez, M.; et al. Polymorphisms associated with fentanyl pharmacokinetics, pharmacodynamics and adverse effects. Basic Clin. Pharm. Toxicol. 2019, 124, 321–329. [CrossRef]

119. Ji, H.; Sahu, N.; Hu, X.; Yao, Y.; He, Y.; Wilkie, D.J.; Molokie, R.E.; Wang, Z.J. Beta2-Adrenergic Receptor Polymorphisms and Haplotypes Associate With Chronic Pain in Sickle Cell Disease. Front. Pharmacol. 2019, 10, 84. [CrossRef]

120. Hoofwijk, D.M.N.; van Reij, R.L.I.; Rutten, B.P.F.; Kenis, G.; Theunissen, M.; Joosten, E.A.; Buhre, W.F.; van den Hoogen, N.J. Genetic polymorphisms and prediction of chronic post-surgical pain after hysterectomy—a subgroup analysis of a multicenter cohort study. Acta Anaesthesiol. Scand. 2019, 63, 1063–1073. [CrossRef]

121. Mishra, A.; Srivastava, R.N.; Awasthi, S.; Parmar, D.; Mishra, P. Expression of Genes and Their Polymorphism Influences the Risk of Knee Osteoarthritis. J. Nucleic Acids 2017, 2017, 3138254. [CrossRef]

122. Seddighzadeh, M.; Korotkova, M.; Källberg, H.; Ding, B.; Daha, N.; Kurreeman, F.A.; Toes, R.E.; Huizinga, T.W.; Catrina, A.I.; Afredsson, L.; et al. Evidence for interaction between 5-hydroxytryptamine (serotonin) receptor 2A and MHC type II molecules in the development of rheumatoid arthritis. Eur. J. Hum. Genet. 2010, 18, 821–826. [CrossRef]

123. Oliveira, A.; Dinis-Oliveira, R.J.; Nogueira, A.; Gonçalves, F.; Silva, P.; Vieira, C.; Silvestre, R.; Carvalho, F.; Medeiros, R. Interleukin-1β genotype and circulator levels in cancer patients: Metastatic status and pain perception. Clin. Biochem. 2014, 47, 1209–1213. [CrossRef]

124. Wu, X.; Kondragunta, V.; Kornman, K.S.; Wang, H.Y.; Duff, G.W.; Renner, J.B.; Jordan, J.M. IL-1 receptor antagonist gene as a predictive biomarker of progression of knee osteoarthritis in a population cohort. Osteoarthr. Cartil. 2013, 21, 930–938. [CrossRef]

125. Rocek, K.A.; Scher, A.I.; Smith, A.; Harris, T.; Eiriksdottir, G.; Garcia, M.; Gudnason, V.; Launer, L.J. Haplootype analysis of the folate-related genes MTHFR, MTRR, and MTR and migraine with aura. Ceptalatalgia 2013, 33, 469–482. [CrossRef]

126. Tse, J.H.; Cheng, M.; Tang, J.P.; Dai, X.J.; Zhang, Y.; Li, X.P.; Liu, Q.; Wang, Y.L. Single nucleotide polymorphisms associated with P2X7R function regulate the onset of gouty arthritis. PLoS ONE 2017, 12, e0181685. [CrossRef]

127. Kambour, O.; Kaunisto, M.A.; Winsvold, B.S.; Wilsgaard, T.; Stubhaug, A.; Zwart, J.A.; Kalso, E.; Nielsen, C.S. Genetic variation in P2RX7 and pain tolerance. Pain 2018, 159, 1064–1073. [CrossRef]

128. Ide, S.; Nishizawa, D.; Fukuda, K.; Kawai, S.; Hasegawa, J.; Hayashida, M.; Minami, M.; Ikeda, K. Haplotypes of P2RX7 gene polymorphisms are associated with both cold pain sensitivity and analgesic effect of fentanyl. Mol. Pain 2014, 10, 75. [CrossRef]

129. Ursu, D.; Ebert, P.; Langron, E.; Munsie, L.; Zou, W.; Fijal, B.; Qian, Y.W.; McNearney, T.A.; Mogg, A.; et al. Gain and loss of function of P2X7 receptors: Mechanisms, pharmacology and relevance to diabetic neuropathic pain. Pain Med. 2011, 12, 1063–1073. [CrossRef]

130. Gavva, N.R.; Sandrock, R.; Arnold, G.E.; Davis, M.; Lamas, E.; Lindvay, C.; Li, C.M.; Smith, B.; Backonja, M.; Gabriel, K.; et al. Reduced TRPM8 expression underpins reduced migraine risk and attenuated cold pain sensation in humans. Sci. Rep. 2019, 9, 19655. [CrossRef]

131. Sereno, M.; Gutiérrez-Raposo, C.; et al. Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy. BMC Cancer 2017, 17, 63. [CrossRef]

132. Yuan, R.; Zhang, X.; Deng, Q.; Si, D.; Wu, Y.; Gao, F.; Zhou, B. Two novel SCN9A gene heterozygous mutations may cause partial deletion of pain perception. Pain 2011, 150, 1510–1514. [CrossRef]

133. Cassio, V.D.; Reis, S.T.; Pimenta, R.; Lucon, M.; Leite, K.R.M.; Srougi, M.; Bruschini, H. Single nucleotide polymorphism analysis in interstitial cystitis/painful bladder syndrome. PloS ONE 2019, 14, e0215201. [CrossRef]

134. Klein, C.J.; Wu, Y.; Kiffoyle, D.H.; Sandroni, P.; Davis, M.D.; Gavrilova, R.H.; Low, P.A.; Dyck, P.J. Infrequent SCN9A mutations in congenital insensitivity to pain with erythromelalgia. J. Neurol. Neurosurg. Psychiatry 2013, 84, 386–391. [CrossRef]

135. Gavva, N.R.; Sandrock, R.; Arnold, G.E.; Davis, M.; Lamas, E.; Lindvay, C.; Li, C.M.; Smith, B.; Backonja, M.; Gabriel, K.; et al. Reduced TRPM8 expression underpins reduced migraine risk and attenuated cold pain sensation in humans. Sci. Rep. 2019, 9, 19655. [CrossRef]

136. Okamoto, N.; Okumura, M.; Tadokoro, O.; Sagawa, N.; Tomida, M.; Kondo, E. Effect of single-nucleotide polymorphisms in TRPV1 on burning pain and capsaicin sensitivity in Japanese adults. Mol. Pain 2018, 14, 97. [CrossRef]

137. Kim, H.; Mittal, D.P.; Iadarola, M.J.; Dionne, R.A. Genetic predictors for acute experimental cold and heat pain sensitivity in humans. J. Med. Genet. 2006, 43, e40. [CrossRef]

138. van Esch, A.A.; Lamberts, M.P.; te Morsche, R.H.; van Oijen, M.G.; Jansen, J.B.; Drenth, J.P. Polymorphisms in gene encoding TRPV1-receptor involved in pain perception are unrelated to chronic pancreatitis. BMC Gastroenterol. 2009, 9, 97. [CrossRef]

139. Backes, C.; Harz, C.; Fischer, U.; Schmitt, J.; Ludwing, N.; Petersen, B.S.; Mueller, S.C.; Kim, Y.J.; Wolf, N.M.; Katus, H.A.; et al. New insights into the genetics of glioblastoma multiforme by familial exome sequencing. Oncotarget 2015, 6, 5918–5931. [CrossRef]

140. Belbin, O.; Brown, K.; Shi, H.; Medcay, W.; Abraham, R.; Passmore, P.; Mann, D.; Smith, A.D.; Holmes, C.; McGuinness, B.; et al. A multi-center study of ACE and the risk of late-onset Alzheimer’s disease. J. Alzheimers Dis. 2011, 24, 587–597. [CrossRef]
166. Christiaens, I.; Ang, Q.W.; Gordon, L.N.; Fang, X.; Williams, S.M.; Pennell, C.E.; Olson, D.M. Two novel genetic variants in the mineralocorticoid receptor gene associated with spontaneous preterm birth. *BMC Med. Genet.* 2015, 16, 59. [CrossRef]

167. Wesselinus, A.; Bours, M.J.; Henriksen, Z.; Syberg, S.; Petersen, S.; Schwarz, P.; Jorgensen, N.R.; van Helden, S.; Dagnelie, P.C. Association of P2X7 receptor polymorphisms with bone mineral density and osteoporosis risk in a cohort of Dutch fracture patients. *Osteoporos. Int.* 2013, 24, 1235–1246. [CrossRef]

168. Cho, L.Y.; Yang, J.J.; Ko, K.P.; Ma, S.H.; Shin, A.; Choi, B.Y.; Han, D.S.; Song, K.S.; Kim, Y.S.; Chang, S.H.; et al. Genetic susceptibility factors on genes involved in the steroid hormone biosynthesis pathway and progesterone receptor for gastric cancer risk. *PLoS ONE* 2012, 7, e47603. [CrossRef]

169. Ter-Minassian, M.; Wang, Z.; Assomaning, K.; Wu, M.C.; Liu, C.Y.; Paulus, J.K.; Liu, G.; Bradbury, P.A.; Zhai, R.; Su, L.; et al. Genetic associations with sporadic neuroendocrine tumor risk. *Carcinogenesis* 2011, 32, 1216–1222. [CrossRef]

170. Gorski, M.M.; Lotta, L.A.; Pappalardo, E.; de Haan, H.G.; Passamonti, S.M.; van Hylckama Vlieg, A.; Martinelli, I.; Peyvandi, F. Single Nucleotide Variant rs2232710 in the Protein Z-Dependent Protease Inhibitor (ZPI, SERPINA10) Gene Is Not Associated with Deep Vein Thrombosis. *PLoS ONE* 2016, 11, e0151347. [CrossRef]

171. Wang, F.; Gelernter, J.; Kranzler, H.R.; Zhang, H. Identification of POMC exonic variants associated with substance dependence and body mass index. *PLoS ONE* 2012, 7, e45300. [CrossRef]

172. Yanovich, R.; Friedman, E.; Milgrom, R.; Oberman, B.; Freedman, L.; Moran, D.S. Candidate gene analysis in israeli soldiers with stress fractures. *J. Sports Sci. Med.* 2012, 11, 147–155. [CrossRef]

173. England, J.; Drouin, S.; Beaulieu, P.; St-Onge, P.; Krajinovic, M.; Laverdiere, C.; Levy, E.; Marcil, V.; Sinnett, D. Genomic determinants of long-term cardiometabolic complications in childhood acute lymphoblastic leukemia survivors. *BMC Cancer* 2017, 17, 75. [CrossRef]

174. de Oliveira, J.G.; Rossi, A.F.; Nizato, D.M.; Miyasaki, K.; Silva, A.E. Profiles of gene polymorphisms in cytokines and Toll-like receptors with higher risk for gastric cancer. *Dig. Dis. Sci.* 2013, 58, 978–988. [CrossRef]

175. Siebert, J.N.; Hamann, L.; Verolet, C.M.; Gameiro, C.; Grillet, S.; Siegrist, C.A.; Posfay-Barbe, K.M. Toll-Interleukin 1 Receptor Domain-Containing Adaptor Protein 180L Single-Nucleotide Polymorphism Is Associated With Susceptibility to Recurrent Pneumococcal Lower Respiratory Tract Infections in Children. *Front. Immunol.* 2018, 9, 1780. [CrossRef] [PubMed]

176. Naumov, D.E.; Perelman, J.M.; Kolosov, V.P.; Potapova, T.A.; Maksimov, V.N.; Zhou, X. Transient receptor potential melastatin 8 gene polymorphism is associated with cold-induced airway hyperresponsiveness in bronchial asthma. *Respirology* 2015, 20, 1192–1197. [CrossRef] [PubMed]

177. Deering-Rice, C.E.; Stockmann, C.; Romero, E.G.; Lu, Z.; Shapiro, D.; Stone, B.L.; Fassl, B.; Nkoy, F.; Uchida, D.A.; Ward, R.M.; et al. Characterization of Transient Receptor Potential Vanilloid-1 (TRPV1) Variant Activation by Coal Fly Ash Particles and Associations with Altered Transient Receptor Potential Ankyrin-1 (TRPA1) Expression and Asthma. *J. Biol. Chem.* 2016, 291, 24866–24879. [CrossRef]

178. Klepstad, P.; Fladvad, T.; Skorpen, F.; Bjordal, K.; Caraceni, A.; Dale, O.; Davies, A.; Klokke, M.; Lundstrom, S.; Maltoni, M.; et al. Influence from genetic variability on opioid use for cancer pain: A European genetic association study of 2294 cancer pain patients. *Pain* 2011, 152, 1139–1145. [CrossRef] [PubMed]

179. Pappas, D.A.; Oh, C.; Plenge, R.M.; Kremer, J.M.; Greenberg, J.D. Association of rheumatoid arthritis risk alleles with response to anti-TNF biologics: Results from the CORRONA registry and meta-analysis. *Inflammation* 2013, 36, 279–284. [CrossRef] [PubMed]

180. Eektemmerman, F.; Swen, J.J.; Böhringer, S.; Huizinga, T.W.; Kooloo, W.M.; Allaart, C.F.; Guchelaar, H.J. Pathway analysis to identify genetic variants associated with efficacy of adalimumab in rheumatoid arthritis. *Pharmacogenomics* 2017, 18, 945–953. [CrossRef] [PubMed]

181. Sadhasivam, S.; Chidambaran, V.; Olbrecht, V.A.; Esslinger, H.R.; Zhang, K.; Zhang, X.; Martin, L.J. Genetics of pain perception, COMT and postoperative pain management in children. *Pharmacogenomics* 2014, 15, 277–284. [CrossRef]

182. Cargnin, S.; Viana, M.; Sances, G.; Bianchi, M.; Ghiotto, N.; Tassorelli, C.; Nappi, G.; Canonico, P.L.; Genazzani, A.A.; Terrazzino, S. Combined effect of common gene variants on response to drug withdrawal therapy in medication overuse headache. *Eur. J. Clin. Pharm.* 2014, 70, 1195–1202. [CrossRef]

183. Dziedziojk, V.; Kurzawski, M.; Safranow, K.; Chlubek, D.; Pawlik, A. The effect of ER1 and ER2 gene polymorphisms on the outcome of rheumatoid arthritis treatment with lefunomide. *Pharmacogenomics* 2011, 12, 41–47. [CrossRef]

184. Canet, L.M.; Calíz, R.; Lupiañez, C.B.; Canhão, H.; Martinez, M.; Escudero, A.; Filipescu, I.; Segura-Catena, J.; Soto-Pino, M.J.; Ferrer, M.A.; et al. Genetic variants within immune-modulating genes influence the risk of developing rheumatoid arthritis and anti-TNF drug response: A two-stage case-control study. *Pharm. Genom.* 2015, 25, 432–443. [CrossRef]

185. Somogyi, A.A.; Sia, A.T.; Tan, E.C.; Collier, J.K.; Hutchinson, M.R.; Barratt, D.T. Ethnicity-dependent influence of innate immune genetic markers on morphine PCA requirements and adverse effects in postoperative pain. *Pain* 2016, 157, 2458–2466. [CrossRef] [PubMed]

186. Maldonado-Montoro, M.; Cañadas-Garre, M.; Gonzalez-Utrilla, A.; Ángel Calleja-Hernández, M. Influence of I6R gene polymorphisms in the effectiveness to treatment with tocilizumab in rheumatoid arthritis. *Pharm. J.* 2018, 18, 167–172. [CrossRef] [PubMed]

187. Menon, S.; Lea, R.A.; Roy, B.; Hanna, M.; Wee, S.; Haupt, L.M.; Oliver, C.; Griffiths, L.R. Genotypes of the MTHFR C677T and MTRR A66G genes act independently to reduce migraine disability in response to vitamin supplementation. *Pharm. Genom.* 2012, 22, 741–749. [CrossRef] [PubMed]
188. Bastami, S.; Gupta, A.; Zackrisson, A.L.; Ahlner, J.; Osman, A.; Uppugunduri, S. Influence of UGT2B7, OPRM1 and ABCB1 gene polymorphisms on postoperative morphine consumption. Basic Clin. Pharm. Toxicol. 2014, 115, 423–431. [CrossRef]
189. Lee, Y.S.; Kim, H.; Wu, T.X.; Wang, X.M.; Dionne, R.A. Genetically mediated interindividual variation in analgesic responses to cyclooxygenase inhibitory drugs. Clin. Pharm. 2006, 79, 407–418.
190. Skarke, C.; Reus, M.; Schmidt, R.; Grunde, I.; Schuss, P.; Geisslinger, G.; Lötsch, J. The cyclooxygenase 2 genetic variant -765G>C does not modulate the effects of celecoxib on prostaglandin E2 production. Clin. Pharm. 2006, 80, 621–632. [CrossRef] [PubMed]
191. Panek, M.; Pietras, T.; Szemraj, J.; Kuna, P. Association analysis of the glucocorticoid receptor gene (NR3C1) haplotypes (ER22/23EK, N363S, BclI) with mood and anxiety disorders in patients with asthma. Exp. Mol. 2014, 8, 662–670. [CrossRef] [PubMed]
192. Chi, X.; Song, S.; Cai, H.; Chen, J.; Qi, Y. Associations of P2X7 Polymorphisms with the Odds of Tuberculosis: A Meta-Analysis. Int. Arch. Allergy Immunol. 2019, 179, 74–80. [CrossRef]
193. Hu, P.; Bader, G.; Wigle, D.A.; Emili, A. Computational prediction of cancer-gene function. Nat. Rev. Cancer 2007, 7, 23–34. [CrossRef]
194. Breivik, H.; Collett, B.; Ventafridda, V.; Cohen, R.; Gallacher, D. Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment. Eur. J. Pain (Lond. Engl.) 2006, 10, 287–333. [CrossRef]
195. Elliott, A.M.; Smith, B.H.; Penny, K.I.; Smith, W.C.; Chambers, W.A. The epidemiology of chronic pain in the community. Lancet 1999, 354, 1248–1252. [CrossRef]
196. Lötsch, J.; von Hentig, N.; Freynhagen, R.; Griessinger, N.; Zimmermann, M.; Doehring, A.; Rohrbacher, M.; Sittl, R.; Geisslinger, G. Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharm. Genom. 2009, 19, 429–436. [CrossRef]
197. Sanger, F.; Coulson, A.R. A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase. J. Mol. Biol. 1975, 94, 441–448. [CrossRef] [PubMed]
198. Sanger, F.; Nicklen, S.; Coulson, A.R. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA 1977, 74, 5463–5467. [CrossRef] [PubMed]
199. Fisher, R.A. On the Interpretation of Chi Square from Contingency Tables, and the Calculation of P. J. R. Stat. Soc. 1922, 85, 87–94. [CrossRef]
200. Emigh, T.H. A comparison of tests for Hardy-Weinberg equilibrium. Biometrics 1980, 36, 627–642. [CrossRef]
201. Mair, P.; Wilcox, R. Robust statistical methods in R using the WRS2 package. Behav. Res. Methods 2020, 52, 464–488. [CrossRef]
202. Carlson, M. org.Hs.eg.db: Genome Wide Annotation for Human. 2020. Available online: https://bioconductor.org/packages/release/data/annotation/html/org.Hs.eg.db.html (accessed on 31 March 2020).
203. Risso, D.; Schwartz, K.; Sherlock, G.; Dudoit, S. GC-Content Normalization for RNA-Seq Data. BMC Bioinform. 2011, 12, 480. [CrossRef]
204. Camon, E.; Magrane, M.; Barrell, D.; Binns, D.; Fleischmann, W.; Kersey, P.; Mulder, N.; Oinn, T.; Maslen, J.; Cox, A.; et al. The Gene Ontology Annotation (GOA) project: Implementation of GO in SWISS-PROT, TrEMBL, and InterPro. Genome Res. 2003, 13, 662–672. [CrossRef]
205. Camon, E.; Magrane, M.; Barrell, D.; Lee, V.; Dimmer, E.; Maslen, J.; Binns, D.; Harte, N.; Lopez, R.; Apweiler, R. The Gene Ontology Annotation (GOA) Database: Sharing knowledge in Uniprot with Gene Ontology. Nucleic Acids Res. 2004, 32, D262–D266. [CrossRef]
206. Bonferroni, C.E. Teoria statistica delle classi e calcio delle probabilita. Encyclopedia Res. Des. 1936, 8, 3–62.
207. Saey, Y.; Inza, I.; Larrañaga, P. A review of feature selection techniques in bioinformatics. Bioinformatics 2007, 23, 2507–2517. [CrossRef]
208. Juran, J.M. The non-Pareto principle; Mea culpa. Qual. Prog. 1975, 8, 8–9.
209. Miller, G.A. The magical number seven plus or minus two: Some limits on our capacity for processing information. Psychol Rev. 1956, 63, 81–97. [CrossRef]